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ABSTRACT 
INTRODUCTION 
          In our country, majority of patients with head and neck malignancies 
present with locally advanced disease. Most of these patients are often found 
unfit for radical surgical treatment or chemo radiotherapy approaches due to 
poor general condition and poor nutritional status. These advanced head and 
neck cancer patients need Palliative Anti-cancer therapy and/or best supportive 
care (BSC).   
AIM AND OBJECTIVES 
Primary Objective:   
          To assess for degree of symptomatic relief & palliation.  
          To assess the proportion of patients eligible for  radical  chemo     
radiotherapy. 
          To assess immediate loco-regional disease control. 
 Secondary Objective: 
          To assess the acute toxicity to the treatment. 
MATERIALS AND METHODS 
          30 advanced and unresectable head and neck cancer patients who 
attended department of radiotherapy were included in this study.  
          All patients were treated with 20Gy radiotherapy in 5 fractions of 400cGy 
each. Response will be assessed after 1 month of radiotherapy. Patients 
achieving  symptom relief of more than 50% and partial response at 
primary/nodal sites with good general condition were treated with further 
chemo radiotherapy at curative intent in 200cGy/# upto a total radiobiologically 
equivalent dose of 66Gy  with  inj.CDDP  40mg/m
2
 weekly. 
          For other patients best supportive care was given. 
RESULTS 
        The study group had 24 male and 6 female patients with median age of 56   
years. Symptom relief of more than 50% noted in 80% of the patients with    
pain, 73% of the patients with dysphagia. Partial response rate after palliative 
radiotherapy 76.6%. Grade 3 and grade 4  toxicity after palliative radiotherapy 
0%. Patients eligible for further chemo radiotherapy at curative intent were 
53%. 6 weeks after further chemo radiotherapy, 18.75% of the patients achieved 
complete response and 75% of the patients left with minimal residual disease. 
DISCUSSION 
There is paucity of guidelines with inadequate information on time dose 
fractionation, toxicity of such palliative regimens and QOL issues. Palliative 
radiotherapy (PRT) regimens should be tailored individually. As per guidelines 
more hypofractionated schedules can be used for end stage patients due to 
limited prognosis and survival. In this study, a short course of hypofractionated 
palliative radiotherapy 20 Gy (5 fractions, 4 Gy per fraction) provided 
appreciable symptom relief with manageable acute toxicity. 
          According to the guidelines, the treatment goal is cure even for advanced 
SCCHN with the intent of maximizing loco-regional control and achieving a 
potential cure. So this study offered further chemo radiotherapy at curative 
intent to good responders of palliative radiotherapy. 
CONCLUSION 
Short course hypofractionated radiation is effective for palliation to 
relieve the symptoms quickly with manageable acute side effects in advanced 
and unresectable head and neck cancers. This study reduce the economic 
burden, treatment time, hospital stay and machine load. It also helps in selecting 
the patients for further chemo radiotherapy.  
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INTRODUCTION 
Globally squamous cell carcinoma head and neck(SCCHN) accounts for 
5.5 million cases every year. It is the 5th most common malignancy worldwide.  
About  300,000 head and neck  cancer cases  die annually, which reflects the 
burden of these cancers.
1.
 
Two thirds of the new cancer cases diagnosed in the world are from 
developing countries like ours. High incidence of oral cavity cancers is reported 
from Australia, India, South Africa and Western Europe
2 
Cancer incidence is 
highest in India among the SAARC countries
3
.
 
Till date there is no single cause or mechanism responsible for causation 
of cancer in human beings. The incidence and prevalence of cancer in a 
geographical area is influenced by the specific environmental conditions 
existing there as well as the life style of that particular population. Hence the 
cancer trends vary from population to population. In India and other developing 
countries like South East Asia, some African countries and South America the 
incidence of  HNC ( Head and Neck Cancer) is high. Contrast to this, the 
incidence of head and neck cancers is very low in Northern Europe and USA. 
INDIA 
HNC is emerging as a major public health problem in India. 
2 
 
These cancers are mostly related to the life style of individuals and 
commonly occurs in 6
th
 and 7
th
 decade of life. Incidence of head and neck 
cancers in India is on rise because of the effective control of the infectious 
disease there by increased longevity of the population.  
More than 200,000 cases of head and neck cancer are reported in India 
every year of which 80,000 cases are oral cavity cancers, 40000 cases are 
pharyngeal cancers excluding nasopharyngeal cancers and 29,000 cases are 
laryngeal cancers. Majority of these cases (60%-80%) in India are presented in 
advanced stage
4
. 
TAMIL NADU 
As per Madras Metropolitan Tumor Registry (MMTR) data, most 
common cancer reported in men is HNC followed by stomach and lung. HNC is 
the 4th commonly occurred cancer in women. Government general hospital, 
Chennai has registered 17.8% of all cancers during the period 2006-2008. HNC 
cancers reported more commonly in men attributable to 25.62% as compared to 
11.35% in women
5
. 
The total number of head and neck cancers  registered in Barnard institute 
of radiology and oncology is 2032 cases in the year 2009, 1939 cases in the year 
2010 and 2104 cases in the year 2011.It constitute 35 to 40% of all new cases 
3 
 
registered in a calendar year.65 to 75% of the patients were presented in 
advanced stages. 
ETIOLOGY 
Many etiological factors have been established in the development of 
SCCHN. Mainly,  
1) tobacco in various forms,  
2) consumption of alcohol, 
3) betel nut chewing, 
4) HPV infection (Human Papilloma Virus), 
5) nutrional factors, 
 
6) occupational exposure, 
7)  poor oral hygiene, ill fitting dentures and sharp teeth, 
8) Immune suppression and genetic factors. 
Smoking 
Smoking was the first identified and established independent risk factor 
for oral, oropharyngeal and laryngeal cancers.
6. 
In India, Tobacco used as 
smokeless (ghutka, as quid with beetel nut chewing, etc..) and smoke (ganja, 
beedies, cigars, pipes, etc..)form. All are responsible for the development of 
SCCHN. Beedi smoking is more hazardous as it is not filtered and the content 
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of tar, nicotine is more compared to manufactured cigarettes. Also they are 
smoked in different ways like reverse smoking which is more harmful. Tobacco 
contains almost 3800 chemicals of which 62 carcinogens have been identified. 
Alcohol 
Alcohol consumption also increases the risk of development of SCCHN. 
The quantity, frequency, type, duration of consumption have all been studied 
and implicated in the development of SCCHN.
7 
Tobacco smoking and alcohol together have synergistic and supra 
additive effect, with duration of consumption, amount, heavy and light 
smokers/drinkers, have all been shown to increase the risk of HNC especially 
oropharyngeal/laryngeal cancer
8
. Pooled analysis by International Head and 
Neck Cancer Epidemiology studied the population attributable risk (PAR) for 
SCCHN, concluded that PAR for tobacco or alcohol was 72% for HNC. Out of 
72%, 33% was due to tobacco alone, 4% was due to alcohol alone, and 35% 
was due to combination of alcohol and tobacco
9
. 
Betel nut chewing 
Betel quid is extensively used in India. It is also called as pan which is 
consists of pieces of areca nut, slaked lime and tobacco. Added to this are 
5 
 
spices, cardamom, cloves, according to the local preferences and are varyingly 
called as gutkha, zarda, mawa, khaini. 
In India betel nut chewing, as quid with tobacco is most common risk 
factor for oral cavity cancer leading to premalignant lesions mainly sub mucosal 
fibrosis and invasive cancer at later date.  
HPV 
HPV has long been thought to play a role in some HNC. One study of 
more than 250 patients used PCR followed by definitive techniques such as 
sequencing and in situ hybridization to search for the presence of HPV in 
HNC
10
. It  was seen in approximately 25% of the lesions, and virtually all were 
high-risk oncogenic types (HPV-16). Remarkably, more  HPV-positivity was 
seen  in the oro pharyngeal cancers. These HPV-positive oro pharyngeal cancers 
were least likely to occur among drinkers and heavy smokers ; least likely to 
harbor a p53 mutation, and had an improved disease-specific survival. Another 
group suggested that human papilloma virus positive cancers may also 
inactivate Rb gene, and harbor a better prognosis. These new data are consistent 
with previous studies of a smaller number of patients
11
 or those that used less 
definitive techniques. It appears that Human papilloma virus positive  
6 
 
carcinomas of ororopharynx compose a distinct clinical and pathologic disease 
entity. 
With the increasing incidence of oropharyngeal cancer in young patients 
who are never smokers/ alcoholics being established, it is attributed to 
increasing incidence of HPV infection; subtypes 16, 18. HPV-related HNSCC 
comprise about 25% of all HNSCC. 50% of oropharyngeal cancers and 0%-
20% oral cavity cancers  positive for HPV DNA
12.
 
Genetic  
In Fanconis Anemia, mutations of the genes like FAA, FAD and FCC 
will lead into the development of lymphoid malignancy and also the risk of 
development of  second primary in tongue, Pyriform fossa and post cricoid 
region
13 
Bloom Syndrome patients who have mutations in helicase genes are 
predisposed to develop solid tumors, 6-8% of which arise in tongue and larynx 
respectively
14 
Homozygotes with ataxia telangiectasia who survive into their twenties 
and thirties are at higher risk of developing T cell Leukemia. Also these patients 
are at increased risk of developing carcinoma of the oral cavity, Stomach, 
Pancreas, Breast, Ovary and bladder
15 
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Xeroderma pigmentosum manifests second primary in the oral cavity in 
addition to primary skin malignancies
(14,16) 
Cowden disease (PTEN), Multiple Endocrine Neoplasia type 1(MEN1) 
and  type 2(MEN II), Neurofibromatis Type II (NF-2) and retinoblastoma (Rb) 
are some of the syndromes associated to primaries in head and neck. 
Nutrition and Cancer 
Vegetable consumption and fish in diet – found to be protective in a case 
control study in India on various head and neck cancers, with two fold  higher 
risk of cancer in non-consumer. 
Plummer vinson syndrome  
 It is characterized by Iron-deficiency anaemia, dysphagia and post-
cricoid webs;  associated with high risk of cancer oral cavity and esophagus. 
PRECANCEROUS LESIONS: 
Lichen planus (erosive form) oral submucosal fibrosis, leukoplakia and 
erythroplakia are known premalignant lesions in head and neck region. 
Leukoplakia 
Most common precancerous lesion is leukoplakia with rate of malignancy 
transformation from <1%-18%
17
. It is treated by  excision. 
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Erythroplakia 
Higher risk of malignant transformation than leukoplakia
18
. 
In histopathological examination, 51%  of the erythroplakia patients was 
found to be invasive cancer;40% of the patients - carcinoma in situ; and 9%  of 
the patients - mild or moderate dysplasia. 
Submucosal fibrosis 
Malignant transformation rare. 
It is an important risk factor in the increase of oral cavity cancers in 
young individuals (< 35 years) in India. 
ANATOMY 
The commonly occurred malignances oh head and neck region are 
usually  arising from oral cavity, nasopharynx, oropharynx, hypopharynx, 
larynx and the paranasal sinuses. Malignances of thyroid gland, eye and brain 
are not included in the head and neck cancers. Although most of them consists 
of squamous cell carcinoma, there are many other histopathological diagnoses. 
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Oral cavity 
The oral cavity contains  the lip, floor of mouth, the anterior two third of 
tongue, buccal mucosa gingiva (upper and lower), hardpalate and retro molar 
trigone. 
Lips 
 The lips are composed of the orbicularis oris. It covered by skin on its 
external surface and mucous membrane on its internal surface. The junction of  
skin and mucous membrane of the oral cavity is called the lip vermilion. The 
blood supply is by labial artery which is a branch of the facial artery. The motor 
nerve supply is by of the seventh cranial nerve branches. The sensory nerve 
supply to the upper lip is  from the infraorbital branch of the maxillary nerve; 
and to the lower lip is  by mental nerve. 
Floor of mouth 
The floor of  mouth is a U-shaped structure  bounded by the lower gum 
and the oral tongue; which terminates posteriorly at the insertion of the anterior  
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Figure -1; Head and neck anatomy 
 
 
tonsillar pillar into the tongue. The two sublingual glands lie immediately below 
the mucous membrane; which is separated by the paired genioglossus and 
geniohyoid muscles. At the point of insertion of these two muscle groups at the 
symphysis are the bony protuberances, the genial tubercles which may interfere 
with the placement of interstitial sources. The mylohyoid muscle arises from the 
mylohyoid ridge of the mandible and is the muscular floor for the oral cavity. It 
ends posteriorly at the level of the third molar tooth. The submandibular gland 
11 
 
situated on the outer surface of the mylohyoid muscle between the mandible and 
the insertion of the mylohyoid muscle. Submandibular duct(Wharton's duct) is 
about five cm long. It lies between the sublingual gland and the genioglossus 
muscle. It  opens in the anterior floor of the mouth  close to the midline.  
 Anterior 2/3
rd
tongue 
The circumvallate papillae is the landmark for the division between oral 
tongue and base of tongue. The arterial supply is mainly by paired lingual 
arteries. The sensory supply is by lingual nerve. 
 Buccal mucosa 
Mucousmembrane covering the inner surface of lips and cheeks is called  
buccal mucosa; ends above and below with a transition to the gingiva. It 
extended posteriorly upto the retromolar trigone. The salivary duct opens into 
the buccal mucosa opposite the second upper molar is the parotid duct. It is 
innervated by a branch of the mandibular nerve , which is sensory  supply to the 
buccal mucosa, and to the skin of the cheek. 
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Gingiva and hard palate: 
The lower gingiva is the one which includes the mucosa covering the 
mandible from the gingivobuccal gutter and extends upto the origin of the 
mucosa on the floor of  mouth. Retromolar trigone lying  behind third molar and  
it is contiguous with the maxillary tuberosity above. The tendinous 
pterygomandibular raphe is present beneath the mucosa of the retromolar 
trigone, which is attached to the pterygoid hamulus and the posterior mylohyoid 
ridge of the mandible and is important in serving as the insertion of the 
buccinator, orbicular oris, and superior pharyngeal constrictor muscles.  The 
pterygomandibular space  lies behind the pterygomandibular raphe and between 
the medial pterygoid muscle and the ascending ramus. It contains the lingual 
and dental nerves. This space is related posteriorly tothe parapharyngeal 
spaceand the deep lobe of the parotid .minor salivary glands are absent in the 
mucous membranes of the alveolar ridges. 
Oropharynx:  
The oropharynx is the continuation of the oral cavity extends from the 
superior surface of soft palate to superior surface of the hyoid bone or vallecula. 
It contains  base of  tongue ,anterior surface of the soft palate and the uvula, the 
13 
 
tonsillar pillars- anterior and posterior. It also contains the glossotonsillar sulci, 
the pharyngeal tonsils, and the posterior and lateral pharyngeal walls. 
Base of tongue 
It is bounded anteriorly by circumvallate papillae, its lateral limit is the 
glossotonsillar sulci, and posterior limit is the epiglottis. The vallecula is a strip 
of mucosa that is in the transition from the base of the tongue to the epiglottis. 
But it is considered a part of the base of the tongue. The muscles of the base of 
tongue are continuous with the anterior two third of the tongue.  
Tonsillar fossa 
Its  anterior limit is  anterior tonsillar pillar, posterior limit is posterior 
tonsillar pillar.Inferiorly bounded by glossotonsillar sulcus and 
pharyngoepiglottic fold. Laterally the tonsillar region is bounded by the 
pharyngeal constrictor muscle and its fascia, the mandible, and the lateral 
pharyngeal space. Glossotonsillar sulcus separate it from base of tongue. 
Beneath the mucous membrane of the sulcus the styloglossal muscle and the 
stylohyoid ligament are present.  
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Soft palate 
It is a thin, mobile muscle complex .The epithelium of oral side of the 
soft palate is squamous while the epithelium of the nasopharyngeal surface is 
respiratory type. It is continuous laterally with the tonsillar pillars.  
 
Larynx 
The larynx is composed of many cartilages connected by ligaments and 
muscles. It is divided on anatomic considerations into the supraglottic, glottic, 
and subglottic regions.  
 
Supraglottis 
Contains of the epiglottis (infra and supra hyoid), false vocal cords, 
ventricles, aryepiglottic folds and arytenoids. The arytenoids are cartilages 
which articulate on the cricoid. 
Glottis 
It contains true vocal cords and its anterior commissure. 
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Subglottis 
The subglottis is 2 cm long . It extends from fivemillimetre  below the 
free edge of true vocal cords to the upper margin of first tracheal ring. The 
preepiglottic space is a potential space bounded by the epiglottis posteriorly, the 
hyoepiglottic ligament and vallecula superiorly, and the thyroid cartilage and 
thyrohyoid membrane anteriorly and laterally. It can be seen as a low-density 
area on a computed tomography.  
The supraglottic structures have a moderate to rich lymphatic supply. The 
lymphatic vessels pass via pre-epiglottic space and thyrohyoid membrane to the 
level II group. some trunks drain directly to  level III or IV group.  
Lymphatics capillaries are absent in the true vocal cords; hence, if any 
lymphnode spread from  carcinoma glottis, is usually due to tumor extension to 
supraglottis or sub glottis.  
The sub glottis has few lymphatic capillaries.  
The lymphatic vessels pass via thyrocricoid membrane to pretracheal  
nodes in the region of isthmus of thyroid, or the trunks may drain into the level 
IV nodes. The pretracheal nodes are midline and, their salient feature is even 
when clinically positive, are 1 cm or less in diameter.  
16 
 
Posterior drainage of subglottis to the level IV nodes is through the 
cricotracheal membrane. 
Hypopharynx 
The epithelium of the pharyngeal mucous membrane is squamous and it 
is continuous with the nasopharyngeal mucous membrane. The dividing point 
between the nasopharynx and posterior pharyngeal wall is the Passavant's ridge. 
It is a musculature ring that contracts to close the nasopharynx during 
swallowing. The thin constrictor muscles of pharynx surround the posterior and 
lateral walls. Between the constrictor muscle and the prevertebral fascia, 
covering the longitudinal spine muscles (longus colli and longus capitis) is the 
retropharyngeal space which is a thin layer of loose areolar tissue. The thickness 
of posterior pharyngeal wall is notmore than one cm in the midline, (from its 
mucous membrane to the anterior vertebral body). Lateral to the pharyngeal 
wall there lies vessels, nerves, and muscles of the parapharyngeal space. The 
constrictor muscles are relatively thin, especially the superior constrictor, and 
do not present much of an obstacle to tumor penetration. There is a variable 
weak spot in the lateral pharyngeal wall which lies just below the hyoid; in this 
region the middle and the inferior constrictor muscles fail to overlap. The lateral 
wall in this area is composed of the thin thyrohyoid membrane, which is useful 
for the penetration by the vessels, nerves, and lymphatics of the 
17 
 
laryngopharynx. The pharyngeal walls are continuous with the cervical 
esophagus below, at the level of upper esophageal sphincter; the transition to 
cervical esophagus is below the arytenoids (C4). The transition zone, 3 to 4 cm 
in length, is the postcricoid pharynx. 
The lateral pharyngeal wall is a narrow strip of mucosa that lies behind 
the posterior tonsillar pillar in the oropharynx, and then continues down into the 
hypopharynx. Here it forms the lateral wall of the pyriform fossa. Posterior 
cornu of the hyoid bone occasionally protrudes into the lateral pharyngeal wall 
on one or both sides, to produce a submucosal bulge. 
 The pyriform fossa is made up of three walls: the anterior, medial, and 
lateral (there is no posterior wall). The pyriform sinus tapers inferiorly to the 
apex and usually terminates variably at a level between the superior and inferior 
borders of the cricoid cartilage. Superior limit of  pyriform sinus is opposite the 
hyoid. The thyrohyoid membrane is lateral to the upper portion of the pyriform 
sinus, and the thyroid cartilage, cricothyroid membrane, and cricoid cartilage 
are lateral to the lower portion. Superiorlaryngeal nerve (internal branch), a 
branch of  vagus, lies under the mucous membrane on the anterolateral wall of 
the pyriform fossa. The auricular branch is sensory to the skin of  back of the 
pinna and the posterior wall of the external auditory canal. 
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The postcricoid pharynx is funnel shaped to direct food into the gullet. 
The superior margin begins just below the arytenoids. The anterior wall lies 
behind the cricoid cartilage and is the posterior wall of  lower larynx. The 
posterior wall is a continuation of  hypopharyngeal walls. Recurrent laryngeal 
nerve lies between the lateral wall and the deep surface of the thyroid gland. 
PATHOLOGY 
Most of the head and neck malignant neoplasms arise from the epithelium 
and are squamous cell carcinoma. Other varieties  of it are lymphoepithelioma, 
spindle cell and verrucous carcinoma. 
Among HNC more than 90% of are squamous cell carcinoma. There are 
three Histological grades are classified on the basis of Keratinisation.  
Well  differentiated- more than 75% of  Keratinisation,  
Moderately differentiated  - 25 to 50% of keratinisation 
Poorly  differentiated-less than 25% of keratinisation. 
In general, poorly differentiated  cancers are more prone for the regional 
metastases, so prognosis is poor. Pathological grade is not a consistent predictor 
of prognosis. Features that predict aggressive behaviour and poor prognosis 
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include perineural spread, lymphatic invasion and extracapsular extension(ECE) 
of lymphnode. 
Morphologically, four types of growth patterns are recognized.  
Ulcerative 
It is the most commonly occurred type. It is oval or round ulcer that is 
friable in nature.  
Infiltrative 
Ulcerative lesions extending deeply into underlying tissues and become 
as an infiltrative growth.  
Exophytic 
It usually grow superficially and metastases occur at later stages when 
compared  to the other types. It looks like an area of thickened epithelium. 
Verrucous cancer 
It is a rare variety, commonly occurs in older age group. Its occurrence is 
associated with poor oral hygiene and ill-fitting dentures. It is  bulky, warty and 
raised fungating lesion. It never give rise to metastases. 
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Other tumor types 
Other less common head and neck cancers are mucoepidermoid 
carcinoma,  
adenoid cystic carcinoma 
adeno carcinoma  
small cell undifferentiated cancer  
Esthesio neuroblastoma (olfactory neuroblastoma). 
Sarcoma 
Melanoma 
Lympho epithelioma 
Hodgkin’s lymphoma  and nonhodgkin’s lymphoma  of  lympnodes of 
the neck and Waldeyar ring. 
FIELD CANCERISATION 
HNC patients  often present with  metachronous or synchronous second 
primary of  aerodigestive tract. Patients with primary cancer may have skip 
lesion which are characterized by pre invasive lesions throughout the field due 
to chronic exposure of carcinogenic agents clinically. Slaughter et al attributed 
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this to a field defect that allowed independent transformation of epithelial cells 
at a number of sites. Then these tumors grew by its own, with genetic 
alterations. For HNC, the working progression model of author allowed direct 
assessment of the genetic alteration  in surrounding areas of abnormality. In all 
cases, surrounding lesions have the same genetic events  of the primary tumor. 
It suggests that independent and geographically distinct skip areas are mainly 
due to single transformed cell. It is observed that a cell is transformed by a 
critical genetic event and begins to migrate through the normal mucosa. 
Additional genetic events in one critical lesion eventually give rise to the 
clinical tumor that is seen on presentation. However, direct molecular 
assessment of surrounding regions confirms the presence of clonal cell 
populations that are not yet fully transformed. Given time, these lesions arise as 
other pre invasive or invasive lesions in the same patient. 
Grades  
Histologically graded into four types 
Grade 1: well differentiation 
Grade 2: moderately differentiation 
Grade 3: poorly differentiation 
Grade 4: undifferentiation 
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Figure – 2  Grade 1 and 2 squamous cell carcinoma 
 
 
PATTERNS OF SPREAD 
Spread is dictated by local anatomy and varies by each anatomical site. 
By  direct  spread muscle  is invaded  and spread along the fascial planes to 
involve adjacent soft tissue structures also occurred. 
Tumor may attach to periosteum or perichondrium but  involvement of 
bone and cartilage is a late event. Bone or cartilage act as barriers to spread and 
its invasion is indicative of a biologic aggressiveness of SCCHN. Slow growing 
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neoplasms of the oral cavity may produce a smooth pressure defect of the 
underlying bone without actual bony erosion. 
Figure – 3   Grade 3 squamous cell carcinoma 
 
Spread of tumor into  space allows superior or inferior spread from base of skull 
to lower neck. 
Perineural spread is observed in muco epidermoid carcinoma which predicts a 
poor locoregional control rate . Tumors with perineural spread  may track along 
the nerve to base of skull, central nervous system and also peripherally which 
may lead to neurological symptoms. 
Invasion of the vascular space leading to the development  of regional and 
distant metastases. 
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Lymphatic spread 
Figure -4 
 
Lymphatic involvement depends on the staging, histology, grade and site 
of the tumor and also the presence of vascular space invasion and the density of 
lymphatics. 
By studying the occurrence of node positive cases by elective neck 
dissection or by determining the probability of regional recurrence, the risk of 
sub clinical disease in a clinically negative neck can be obtained. The relative 
incidence of clinically positive nodes determined by anatomic site of primary 
and T stage. Well lateralized lesion will spreads to ipsilateral neck. Midline 
lesions spread to both side;carcinoma of tongue base and nasopharynx will 
involve both sides of neck even when it is situated  well laterally 
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Table – 1  Lymphatic drainage of neck 
Ia Submental group 
Ib Submandibular group 
II  Upper cervical  group  
III  Mid cervical group 
IV  Lower cervical group 
(transverse cervical) 
V  
 
Spinal accessory chain lymph 
nodes 
VI Prelaryngeal, pretracheal, 
paratracheal group 
 
Patients with large or multiple clinically positive ipsilateral nodes are at 
risk of developing contralateral disease. 
Disturbance and obstruction of the lymphatic pathways by surgery or 
Radiotherapy shunts the lymphatic flow to the opposite side. Contralateral 
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metastases  from a well lateralized lesions most commonly involves the level II 
node; sometimes may be bypassed the level II and involves level III or level IV. 
The incidence of retropharyngeal adenopathy is based on  the primary site 
and presence of clinically involved nodes. 
Involvement of lymph node levels are predictive of the primary site. Lip 
and oral cavity tumors spread to level I initially. Larynx and pharyngeal  
cancers  involves  levels II and III. 
 
Distant spread:(haematogenous spread) 
Risk of distant metastases are related to neck stage(N stage) ,lymph node 
location and site of primary. Risk is less than 10% for N0 or N1 neck and 30% 
for N3 and N1 or N2 below thyroid notch. Hypopharynx and oropharynx 
carcinomas give distant metastases more commonly than oral cavity. 
Lung is the commonly involving organ in metastatic SCCHN  (50%) 
 
HISTORY AND DIAGNOSTIC WORK -UP  
Detailed clinical history of the patient including the history of usage of 
tobacco, alcohol, oral sex, and other environmental exposures which are 
mentioned in etiological risk factors should be taken. Patient with symptoms 
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suggestive of malignancy  of upper aerodigestive tract of more than  two weeks 
duration or with an asymptomatic neck mass should be evaluated  further 
carefully. 
PHYSICAL EXAMINATION  
Thorough physical examination can find even the early lesions of the 
aerodigestive tract and also the multiple primaries which are common in upper 
aerodigestive tract. This will also indicate the severity and the duration of the 
disease.  
Physical examination should be done in a systematic manner so that any 
point is not going to be missed. Frequently overlooked part of the examination 
like searching for ulcers, nodules, pigmented and other suspected lesions should 
be done carefully.  
Cranial nerve examination is must for all patients of head and neck tumor 
or mass. Any discharge, bleeding and drainage from eyes, nose and ear to be 
looked for. 
Examination of the oral cavity should be done completely. Looking for 
halitosis and Trismus is must. Bimanual palpation of the floor of mouth, tongue, 
buccal mucosa should be done with one finger inside the mouth and other 
outside the mouth. Mandible is to be palpated for involvement; any tenderness, 
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thickening, discharge, sinuses etc to be noted and biopsy of the suspected lesion 
is to be taken.  
Nose 
External nose, anterior nares, alae and vestibule should be carefully 
examined.  
Neck 
Neck examination is to be done systematically to look for the location of 
any mass. Neck examination should be done by inspection, palpation, 
percussion and Auscultation. Palpation is an important step in the examination 
of neck.  Mass and the nodes are palpated between the thumb and index or 
middle finger.  
The location, size, consistency, fixity and tenderness of the node to be 
examined. 
Posterior Rhinoscopy:-To see choane, entire nasopharynx .  
Anterior rhinoscopy:-To see the vestibule, nasal septum, lateral wall 
and floor of the nasal cavity.  
Indirect Laryngoscopy: For examining the Base of the tongue, Vallecula, 
hypopharynx and the larynx. Inspection and mobility of the vocal cords is to be 
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evaluated. This provides an overall picture of the mobility and asymmetry 
indicating the presence of an occult tumor.  
Direct Laryngoscope:-Thorough visualization of the nasal cavity, 
nasopharynx, oropharynx, hypopharynx and larynx can be done and pooling of 
secretions to be noted. Individual subsites also to be  looked into for any 
doubtful lesions.  
Endoscopy:-Because of the field cancerisation patient with Head and neck 
malignancy will have a 5% of chance of Synchronous primary that is SCCHN, 
lung or oesophagus. Laryngoscopy(direct), oesophagoscopy and bronchoscopy 
(Triple endoscopy)  to be done in all patients with an unknown primary  and in a 
known primary of HNC and doubtful lesions are biopsied. These can also 
provide details about the extension of disease.  
DIAGNOSTIC IMAGING  
Chest X-ray – to see for any  pulmonary metastases or a second primary. 
Orthopantomogram  
To look for involvement of bone in oral cavity lesion.  
USG 
Ultra Sound scan is not of much use in the management of SCCHN. 
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CT Scan 
 It delineates the extent of the tumor( both primary and secondary) and 
can differentiate the solid from cystic lesion.  
The site of an unknown primary with secondary neck node can be 
identified by CT scans of chest, abdomen and pelvis. It has advantage over MRI 
in detecting bony erosions. With its high spatial resolution fat, muscle, bone and 
other soft tissues are easily identified. 
Dynamic contrast CT[DCC]  
With the use of less contrast agent, it able to differentiate blood vessels 
from malignant mass and lymph nodes. 
Spiral CT 
Faster than DCC and it has the capacity for multiplannar reconstruction 
without compromising on the quality of scan. 
MRI 
 It gives information about the size, location and the extent of the tumor 
accurately. Gardolinium enhanced MRI is very useful than CT for imaging 
nasopharyngeal  and oropharyngeal carcinoma. 
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  Main disadvantage is movement artifact particularly in larynx and 
hypopharyngeal carcinomas. 
STAGING 
The staging for the primary lesions (T) is done by using   The American 
Joint Committee on Cancer (AJCC) (2010). The AJCC (2010) neck staging (N) 
is common to all head and neck sites, except the nasopharynx
19
. 
T staging is done purely depending on the individual site.  
But N staging remains common for all. 
N staging of HNC 
NX Regional lymph nodes cannot be assessed  
N0  No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm 
or less in greatest dimension 
N2  Metastasis in a single ipsilateral lymph node 
More than 3 cm but not more than 6 cm in greatest dimension, or in 
multiple ipsilateral lymph nodes, none more than 6 cm in greatest    
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dimension or in bilateral or contralateral lymph nodes, none more 
than 6 cm in greatest dimension. 
N2a  Metastasis in a single ipsilateral lymph node,  
more than 3 cm but not more than 6 cm in greatest dimension. 
N2b  Metastasis in multiple ipsilateral lymph nodes,  
none more than 6 cm in greatest dimension. 
N2c  Metastasis in bilateral or contralateral lymph nodes, 
none more than 6 cm in greatest dimension. 
N3 Metastasis in a lymph node, more than 6 cm in 
greatest dimension. 
TREATMENT OVERVIEW 
For practical purposes, SCCHN can be divided into 3 clinical stages:  
1) early disease 
2) locoregionally advanced disease 
3)  Metastatic/recurrent disease. 
Of these 50-60% is locally advanced atpresentation. 
Treatment approaches for each stage vary.  
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EARLY STAGE DISEASE  
Usually single modality treatment with either Surgery or Radiotherapy 
provides comparable and efficacious locoregional control and survival results. 
 
Surgery 
Surgical resectability of a head and neck cancer is assessed by a 
multidisciplinary team. An adequate margin of 1.5 cm to 2cm is required to 
obtain a clear frozen section. Any suspected margin of < 2 cm has to be 
examined by a frozen section. A clear margin is defined as a distance of ≥ 5 mm 
from the resected margin to the invasive tumor. A close margin is a distance of 
< 5 mm. Primary is usually approached through a trans oral, transcervical or, 
through mandibulectomy.     
Reconstruction is done by using skin graft, free tissue transfer, regional 
flap, or by primary closure. Reconstructed area should functionally and 
cosmetically resemble the resected tissue. 
Neck  dissection:                    
Elective neck dissection is done in clinically node negative neck. 
Therapeutic neck dissection is done in clinically apparent nodal disease. Based 
on the clinical, radiological and preoperative finding, therapeutic dissections 
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may be either selective or a comprehensive neck dissection. Tumors 
approaching midline or tumors with bilateral lymphatic drainage like base of 
tongue, palate, and supraglottis should undergo dissection in both sides of neck. 
 
Radiotherapy: 
Primary disease and involved neck nodes are to be treated by 66 to 70 Gy 
of radiotherapy in conventional 2 Gy fractions. Low to intermediate risk lymph 
nodes are to be treated electively between 44 and 60 Gy. Advanced tumor stage, 
depth of invasion, perineural invasion, multiple node positivity, vascular 
invasion and lymphatic invasion require postoperative radiotherapy. Post 
operative chemo radiotherapy is indicated when there is extra capsular 
extension and positive margins. Postoperative radiotherapy is usually 
administered in 6 weeks or less.  Radiation may be delivered either in 
conventional or altered fractionation. 
 
Surgery vs radiotherapy 
The advantages of surgery over radiotherapy are one time procedure, 
limited amount of tissue is exposed to treatment and shorter hospital stay. 
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Also disadvantage of radiation like acute and late toxicity can be avoided and 
radiation can be reserved for salvage purposes and second primaries. The 
advantage of radiation therapy is organ preservation and thereby function 
preservation.  
 
LOCOREGIONALLY ADVANCED CANCERS 
Aggressive multimodality treatment is needed to achieve cure in these 
patients. Therapy for locally advanced SCCHN has the major goals of 
eradicating locoregional disease, treating distant micrometastases, preserving 
organ function, and minimizing toxicities. 
In the past, 5 year survival  for loco regionally advanced cancer was only 
forty percent. (ten to thirty percent for patients with stage IVa and IVb tumors). 
Most  of the patients developed recurrence due to loco regional failure. More 
than fifty percent of patients who die from HNC have locoregional disease as 
the only site of failure, and almost 90% of patients with distant failure also have 
persistent locoregional disease. Therefore, the efficacy of any curative approach 
is measured by its ability to achieve locoregional control
20
. Historically, 
locoregionally advanced tumors were treated with surgery (with or with out 
adjuvant radiotherapy) or radiotherapy alone. Small  amount of patients only 
had an adequate surgical resection, and the outcomes were poor with respect to 
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survival and organ preservation. Furthermore, radiotherapy alone is not 
sufficient to successfully treat most HNC at locoregionally advanced stages. 
Altered fractionation schedules have also been studied clinically. Even the most 
effective RT regimens result in local control rates of 50% to 70% and Disease 
Free Survival (DFS) of 30% to 40% 
21
. 
 Hence multimodality treatment is necessary to achieve good locoregional 
control. 50% to 60% of locoregionally advanced cancer patients develop 
locoregional recurrence within two years  even after surgery, radiotherapy, or 
both and 20% - 30% of patients  landed in distant metastases. So chemotherapy 
was investigated to maximize the response along with Radiotherapy – as 
induction, concurrent and adjuvant chemotherapy
21
. 
Induction chemotherapy 
Overall response  rate of  induction chemotherapy using cisplatin and 5Fu  
that shown in various trials is 60 complete response rate is 20 to 30%. It also 
decreased the occurrence of distant metastasis because of the early effect on 
micro metastasis in the circulation. But induction chemotherapy failed to 
showany  survival benefit. The recent phase III randomised trial (DeCIDE trial) 
which using docetaxel, cisplatin and 5FU as a induction chemotherapy followed 
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by concurrent chemo radiation also failed to show any survival benefit when 
compared to concurrent chemo radiation 
22
. 
Concurrent chemo radiation 
Concurrent chemoirradiation has shown clinically significant benefit with 
better locoregional control as well as survival benefit. During the past 2 decades 
definitive concurrent chemoirradiation has shown to improve survival and organ 
preservation in locally advanced Head and Neck Cancer 
23
.Recent meta-analysis 
reveals an survival benefit ( absolute) of 4.5% for chemoirradiation 
(neoadjuvant, concurrent, adjuvant chemoradiation) in SCCHN, and 6.5% for 
concurrent chemoradiation over RT alone 
24
. The advantage of the adding  
chemotherapyto historical treatment is same in all sub sites of SCCHN
25
. 
Concurrent platinum based chemoradiation regimens have demonstrated 
improved disease control rates compared to those obtained using radiotherapy 
alone and is the most commonly used chemotherapeutic agent in clinical use 
24
,  
with manageable toxicity. So  at present the standard of care in patients with 
locally advanced  and unresectable head and neck cancer is concurrent chemo 
radiation using  Single  agent high dose cisplatin. 
Increased toxicity is noticed in combination chemotherapy group. The 
purpose of adding chemotherapy to radiation is to enhance the effect of 
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radiation. So it is important to complete the radiation therapy within the 
scheduled time. It is not good to interrupt radiation in between because of  acute 
toxicity of  combination chemotherapeutic agents. So single agent 
chemotherapy is preferred. 
Adjuvant chemotherapy 
The use of adjuvant chemotherapy has a theoretical benefit of eradicating 
the sub clinical disease left behind after chemo radiation. The increased 
sensitivity of minimal residual disease to anticancer drugs has been shown by 
cell cycle and growth fraction studies. It is also postulated that adjuvant 
chemotherapy sterilizes the micro metastasis present in the circulation and 
thereby prevent distal recurrence rate and improve overall survival rate. 
Unfortunately these theoretical benefits are not proved by any randomised 
control trials. So its use is far from definitive. 
 
PALLIATION 
But in the developing country like India, majority of the locally advanced  
HNC patients are often found unfit for radical  combined modality treatment 
due to poor nutritional status and poor general condition. These patients need  
palliative anti cancer therapy and/or best supportive care(BSC).  
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PALLIATIVE RADIOTHERAPY (PRT) 
Palliative radiotherapy (PRT) offered, effective palliation and improved 
the  quality-of-life in advanced and unresectable SCCHN
26
 and accounts for a 
significant amount of cancer care across the world. However, studies are very 
minimal about Palliative radiotherapy in HNC. Poor compliance to therapy and  
limited inclusion in prospective trials render outcome assessment difficult and 
challenging in  these patients. Furthermore, limitation in resources both in terms 
of personnel and radiation equipment in developing countries like India has led 
to a situation where timely delivery of PRT to patients with short life 
expectancy is compromised. An expert panel had earlier concluded that 
insufficient information precludes estimations of the frequency, degree of or 
duration of symptomatic relief from PRT of HNC
27
.There is no general 
consensus in the  current literature regarding the optimal choice of palliative 
regimens for these patients. There is paucity of guidelines with inadequate 
information on time dose fractionation, toxicity of such palliative regimens and 
QOL issues. PRT regimens should be tailored individually. Severe toxicities 
due to radiotherapy should be avoided when treatment is for palliation. 
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Recommended PRT schedules are  the following  
50 Gy in 20 # (fractions) 
30 Gy in 10 # 
30 Gy in 5 # 
60 Gy in 30 # 
37.5 Gy in 15 # 
More hypofractionated schedule can be used for end stage patients due to 
limited prognosis and survival. 
 
SELECTION OF PATIENTS FOR PALLIATIVE INTENT 
TREATMENT 
According to  the guidelines, the treatment goal is cure even for advanced 
SCCHN with the intent of maximizing loco-regional control and achieving a 
potential cure. So it is hard to find the exact patients with advanced disease  
eligible for palliative treatment alone as compared to those in whom radical 
intent treatment could still be considered.  
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The  following factors  can guide the oncologist about patients selection for 
palliative intent treatment alone. 
1) fixed, unresectable  and inoperable tumors (primary and secondary) 
 
2) very advanced, incurable loco-regional cancer with poorgeneral condition 
and medical comorbidities; 
3) metastatic disease and patients with limited expected survival. 
 
BEST SUPPORTIVE CARE 
Best supportive care includes 
1) Management of   pain and vomiting 
2) Management of  anemia due to cancer and cancer treatment 
3) Management of fatigue due to cancer 
4) Management of distress due to symptoms. 
5) Prevention and treatment of infections due to cancer. 
6) Palliative care and nutrition support. 
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PROGNOSTIC FACTORS 
Neck node involvement is the single most important factor in determining 
the survival of a HNC (beside tumor status).  
Neck node involvement reduces the 5 year survival rate by 50%. 
Nodal size (N2 or N3) and extra capsular extension are distinct 
prognostic features. The risk of neck failure and poor survival are fairly high. 
Multiple lymph node involvement or contralateral nodal metastasis 
denote a poor treatment outcome. 
 
 
 
  
  
 
LITERATURE 
REVIEW  
  
43 
 
LITERATURE REVIEW 
VERY ADVANCED HEAD AND NECK DISEASE 
Very advanced head and neck diseases are following 
1)Newly diagnosed locally advanced disease 
2)Unresectable nodal disease which is newly diagnosed 
3)Persistent or recurrent tumors 
4)Metastatic disease 
5)Patients not suitable for surgery. 
Treatment option for these advanced and unresectable cases  is mainly 
based on the Eastern Cooperative Oncology Group(ECOG) Status. For ECOG 1 
and 2 patients, concurrent chemoradiation can be given. Palliative RT or best 
supportive care is the option for patients with  ECOG 3. 
 
Previous Palliative  radiotherapy trials  
Best supportive care alone is shown a median survival of 3 to 6 months in 
advanced Squamous cell carcinoma of head and neck
28
. In  one of the largest 
studies
29
 on the natural history of untreated HNC, 808 patients were followed-
44 
 
up until their death. All the patients were given best supportive care, but 
specific cancer treatment was not done due to advanced disease status, poor PS 
or patient refusal to the treatment. The median overall survival was 100 days 
ranged from 1 day to 53.8 months. PS was the only predictor of survival 
(P<0.001) on multivariate analysis.  50% of untreated patients died within 4 
months of diagnosis, but a small subset of patients with low tumor burden and 
good  PS (performance status) survived upto 4 years. It has been  concluded and 
argued that PRT neither improves survival, nor positively impacts on QOL of 
patients with SCCHN. 
Burns et al 
30 
conducted a study on 76 patients with advanced cancers of 
the upper aero-digestive tract with radical or palliative intent. Clinical stage, 
tumor site and performance status were important prognostic factors. Overall 
mean survival was 15 months with a 2-year disease-free survival of 16%. 
Patients treated with radical approach  had a mean survival and 2-year disease-
free survival of 19.4 months and  29% respectively. On the other hand, 
palliative intent treatment was associated with a mean survival of 8.4 months 
and virtually there were no long-term survivors. Appreciable  palliation was 
achieved in 25% of patients , but the remaining patients continued to have pain, 
significant distressing symptoms related to speech and swallowing. The results 
of palliative intent treatment was not better than best supportive care leading the 
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authors to conclude that there is small benefit associated with palliative  
treatment  in SCCHN. 
 
There is no high level evidence regarding the use of palliative head and 
neck radiotherapy, but several retrospective studies
(31.32.33) 
case-control studies 
(34,35)
 single arm prospective studies
(36,37,38,39,40) 
and one small randomized 
controlled trial 
41.
 confirms that palliative treatment  is associated with an 
improved outcome. 
 
In a retrospective study,
31 
 40 cases of  unknown primary with advanced 
neck nodes were treated with 30 Gray in 10 fractions over 2 weeks  and 20 Gray 
in 2 fractions with one week  break in between. There was a good one year 
response rate (77% and 48% respectively), with a similar symptomatic response 
rate of 68% and 38% respectively. 
 
Lusinchi et al 
32
 studied 54 patients with  palliative radiotherapy(30 
Gy/15 fractions/3 weeks). Good responders were taken up for further 
radiotherapy of curative doses with or without treatment breaks. Radiotherapy 
was discontinued in 18/54 (33%) patients even before the planned 30 Gy due to 
poor PS, intolerance to Palliative radiotherapy, progression of disease and 
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logistical reasons. Local control rate at 3 years was 19%. The 2 year overall 
survival and 5 year overall survival for patients received   Palliative radiation 
was 16% and 5% respectively.  
 
Cyclical accelerated split course radiotherapy with concurrent 
chemotherapy was offered to 34 patients with advanced unresectable 
SCCHN
34
.Radiotherapy dose was 23.4 Gray in 9 days divided into 1.8 Gy, two 
times daily  for a total tumor dose of 70.2 Gray  in 3 cycles (51 days). The two 
year local control and survival was 81% and 58% respectively. Excellent 
palliation  was achieved with acceptable overall toxicity. This result was 
comparable to historical controls treated with palliative radiotherapy. 
 
Carvalho et al 
35.
compared patients with advanced  HNC who received 
treatment with those who remained untreated until death having the same 
demographic and clinical characteristics. They found a significant difference 
between the survival rates of the untreated group and those of the treated groups 
that was independent of the type of treatment performed ( P< 0.00001) or the 
tumor response to treatment ( P < 0.0001). 
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Paris et al
36 
conducted a study which has given fractionationated 
radiotherapy of 370 cGy per fraction given daily 2 times for 2 days, totally 4 
fractions. It was repeated every three to four weeks giving a total dose of 44 
Gray in 9 weeks. Good palliation was achieved in 33 (84.6%) of 39 lesions in 
37 patients with minimal acute toxicity. The mean survival was 4.5 months 
ranged from 2 weeks to 31 months. 
 
Minatel et al 
37.
conducted a study  on 58 patients with split course 
radiotherapy, 50 Gy in 20 fractions with a  treatment gap of two weeks after the 
first 25 Gy with concurrent chemotherapy bleomycin. Study result was 69% 
local control rate with median response of 7 months. Symptom relief  was 
observed in 81% of patients, but there was increased  grade 3 toxicity(79%). 
 
25 advanced SCCHN patients were given short course  Palliative 
radiotherapy of 30 Gy in 10 fractions over 2 weeks
38.
 Baseline symptoms were 
assessed with an 11-point numerical .At 1-month after PRT , all 22 patients with 
pain and  more than 90%  of the patients with swallowing difficulty, respiratory 
distress and insomnia showed>50% symptomatic relief. Cough was relieved in 
60% patients. The median duration of symptom relief  was 3 months. No grade 
3  toxicity was noted. 
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The QUAD SHOT 
40.
delivered   14 Gy in 4 #, two times daily with  6 
hours gap period for two consecutive days. Then the same schedule was again 
given at four weekly interval for a further two courses, if there was no tumor 
progression. Like that maximum cumulative dose of 42 Gray in 12 # was given. 
16 patients (53%) had an objective response and  7 patients had shown  static 
response. Median overall survival was 5.7 months ranged from 0.6 to 26.7 
months, with a median progression-free survival of 3.1 months ranged from 0.6 
to 11.4 months. Grade 3 toxicity was nil. Patients were asked to rate their 
quality of and to comment whether they thought radiotherapy was useful. 
Performance status was improved in 67% of the patients. All patients were 
tolerated the radiotherapy well and QOL was improved in 11 of 25 (44%)  
patients. Treatment was thought to be worthwhile by 43%, 58% and 63% of 
patients after first, second and third courses of cyclical radiotherapy 
respectively. 
 
So what is the optimum dose-fractionation schedule? 
In the last decade or so,  there were lot of clinical trials  established that  
short course PRT was effective in incurable solid tumors like  bone 
metastases,
26 
brain metastases
 (26a)
 and lung cancer 
(26b)
.  But there was no such 
trials for palliative radiotherapy in advanced and incurable SCCHN. It has been 
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a argument that  a higher total dose is needed for growth restraint and durable 
palliation in HNC. Various dose-fractionation schedules that have been used in 
the above mentioned sites have been extrapolated for use in HNC palliative 
radiotherapy. Although the quality of evidence is not very clear, the weight of 
evidence favours a short course fractionated regimen  like 20 Gy in 5 fractions 
or 30 Gy in 10 fractions as compared to single fraction or protracted courses of  
palliative radiotherapy. 
 
SELECTION OF PATIENTS FOR  FURTHER RADIOTHERAPY 
(DOSE ESCALATION)  
Good responders to PRT have traditionally been treated with further 
radiotherapy of   curative doses
39.
 
Mohanti et al 
39
conducted a study on 505 stage IV SCCHN patients. All 
patients were given a dose of 20 Gy , 4 Gy/#,  total 5 fractions over one week. 
Seventy percent of patients presented with two or more distressing symptoms.  
On assessment at one month post PRT189  patients(37%) attained a partial 
response and had  became ambulatory. These patients were well suited for 
further  radiotherapy. Good symptomatic  relief (50% or more) was observed  in 
57% for pain, 53% for swallowing difficulty, 57% for voice change, 47% for 
ear pain, 76% for dyspnoea and 59% for cough. The main acute toxicity of PRT 
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was grade 2 mucositis and dermatitis. Median overall survival with palliative 
radiotherapy was 200 days. The 153 patients were received further radiotherapy 
with curative intent had a significantly better overall survival of 400 days. 
 
Rajan Paliwal et
42.
al treated 50 stage 4 disease SCCHN patients with a 
total dose of 20 Gy,4 Gy per fraction, total of  5 fractions. Majority of patients 
(60-70 %) had symptom  relief of more than 50%. Further radiotherapy was 
given  according to tumor regression status of the patients. 
 
A study conducted by Agarwal et al 
43
where palliative radiation 40 Gy in 
16 # in 3½ weeks was given. Disease  regressed patients with acceptable acute 
toxicity were received  dose escalated radiotherapy up to a maximum dose of 50 
Gray. Complete response was seen in10 percent of the patients; while partial 
response  was seen in 63% of the patients after 6 to 8 weeks of completion of 
radiotherapy. progression free survival at 1 year was 55.1%. At completion of 
radiotherapy a 57% of patients showed 50% to 75% of symptom relief while 
17%  showed more than 75% symptom improvement as compared to baseline in 
symptoms like  pain,  swallowing difficulty , and voice change. However this 
study results in grade 3 mucositis and grade 2 xerostomia in more than 50% of 
the patients. 
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Ali My et al 
44.
conducted a study comprising 30 locally advanced 
SCCHN patients who were treated initially by  palliative radiotherapy 30 Gy  in 
3 Gy per fractions. Patients attaining more than 50% symptomatic  relief and 
partial response at primary and nodal site and in good general condition  after 
one month of palliative radiotherapy  were  taken up for further radiotherapy 
with curative intent. Further radiotherapy was given in 2 Gray per fractions upto 
a total radiobiologically equivalent dose of 66 Gray  with same radiation portals 
that were used in PRT. Spinal cord shielding was done at 40 Gy. Further dose 
was  calculated by Time-Dose-Fractionation (TDF) method taking into account 
the dose fraction of palliative radiotherapy with gap correction. 
 
TUMOR REPOPULATION  DUE TO TIME INTERVAL GIVEN FOR 
DOSE ESCALATION 
In locally advanced SCCHN, inferior  clinical results with radiotherapy 
and chemotherapy is due to accelerated repopulation of the cancerous cells 
45
. 
Cytotoxic injury to squamous cancer cells respond by increased mitotic rate as 
happened in normal cells since these cells retain some homeostatic control 
45
.Tumour repopulation mechanisms are similar to normal tissue repopulation. 
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Prolongation of treatment time results in repopulation of stem cells which are 
surviving the treatment. 
Tumour repopulation mechanisms: 
Locally advanced SCCHN tumours respond to cytotoxic effect of 
radiotherapy and chemotherapy by increasing the  mitosis of surviving stem 
cells. 
Cell recruitment – from pool of quiescent cells. 
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Three A’s of repopulation:  
• Stem cell division acceleration. 
• Abortive division. 
• Asymmetrical loss in stem cell division 
 
Single agent chemo vs Combination chemotherapy 
Concurrent chemoradiation  can be given by  using single  or multiple 
agents of chemotherapy with radiotherapy. The  single agent  mitomycin C- bio 
reductive alkylating agent, has been studied extensively. Mitomycin is cytotoxic 
agent which is active against hypoxic cells thereby increase the therapeutic 
ratio. The other single agent chemotherapy drugs usedfor  concurrent chemo 
radiation are cisplatin, 5-flurouracil and methotrexate.  
Because, initial  trials with single agent chemotherapy  plus radiotherapy 
showed improved  loco regional control and overall survival, people started 
using combination chemotherapy concurrently with radiation. The combination 
of cytotoxic drugs like cisplatin and 5 fluorouracil is highly active against 
squamous cell carcinoma of head and neck. But  more toxicity was occurred 
while using combination chemotherapy concurrently with radiation and it 
required more supportive care.  
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Because of  increased toxicity in combination chemotherapy, it is not 
advisable  in a setting where intensive supportive care cannot be provided. The 
purpose of giving chemotherapy concurrently with radiation is to enhance the 
radiation effect. So it is  important to complete the radiation therapy within the 
prescribed time. Also  It is not good to interrupt the radiation in between due to  
increased acute toxicity of combination  chemotherapy drugs. Hence, 
concurrent use of single agent cisplatin along  with radiation is the standard of 
care for SCCHN. 
 
Three  weekly chemo vs Weekly chemo  
The dose of single agent cisplatin is 100 mg/m
2
of body surface area every 
three weekly. There is  increased toxicity like  mucositis, vomiting and renal 
toxicity noted  with this three weekly dose of cisplatin. This needs more 
intensive supportive care and  more resource implications. This also results in 
frequent interruption  of treatment and poor patients compliance. Therefore it is 
logical to give the cisplatin weekly instead of giving three weekly to reduce the  
toxicities and increase patients compliance to treatment . Many trials have 
showed that weekly cisplatin is a safe and less toxic than three weekly cisplatin. 
So weekly cisplatin is  more acceptable and better alternative to three weekly 
cisplatin  without compromise the efficacy.  
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A study  conducted by Akihiro Homo et al on  53 locally advanced  
SCCHN patients by  using weekly cisplatin 40 mg/m
2 
 with  70 Gy of 
radiotherapy in 35 fractions
47
. The overall survival rate and disease free survival 
was 93.7% and  88% respectively. All patients except one showed   manageable 
toxicities.This study proved that weekly cisplatin is a better  alternative with 
less toxicity without compromising the results. 
 
The Basket University conducted  a retrospective analysis on  53 SCCHN 
patients has shown that there was no significant difference in median overall 
survival in weekly  and three weekly cisplatin arms. The loco regional control 
rate and distant relapse rate  were similar in both arms . They have  concluded 
that  concurrent chemo radiotherapy with weekly cisplatin is as effective as 
three weekly cisplatin with very high bolus dose 
48
. 
 
A study conducted by Tejpal Gupta et al at Tata Memorial Hospital, 
Mumbai on 264 cases with locally advanced SCCHN . All patients were given a 
66 – 70 Gy radiotherapy  with weekly cisplatin 30 mg/m2. 65% of patients  
received planned cisplatin dose. The 5 year loco regional control was 46 %. The 
incidence of grade 3 mucositis was 29 %. The conclusion of the study was 
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weekly cisplatin has shown moderate efficacy with  manageable  toxicity. They 
have also concluded that weekly cisplatin is an optimal chemotherapeutic agent 
especially in a limited resource setting
49
. 
 
Tray nor et al, University of Wisconsin conducted a study about 
feasibility of weekly cisplatin with Intensity modulated Radiotherapy (IMRT) in 
locally advanced SCCHN. enrolled 57 patients were received  weekly cisplatin 
dose of 30 mg/ m
2
. The radiotherapy dose to gross tumor volume was 70 Gy. 
The study was conducted during a period of November 2001 to May 2007. The 
loco regional control  and median overall survival was 85.5% and 86.9% 
respectively. The conclusion of  the study was weekly cisplatin 30 mg/m2 along 
with IMRT with a GTV dose of 70 Gy is well tolerated 
50
. 
 
In summary weekly cisplatin is well tolerated , less toxic  and as effective 
as three weekly cisplatin for treating SCCHN patients concurrently along with 
radiation. 
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CISPLATIN 
( cis-Diamminedichloroplatinum) 
 
Classification: 
Platinum compound, cytotoxic. 
 
Mechanism of action: 
 It binds covalently to DNA and disrupts DNA function. It  is similar to  
other the alkylating agents in action. 
 It binds covalently to DNA and inhibit  the function of DNA. Once  it 
entering into  the cells, water molecules are replacing the chloride ligands. 
Because of this, positively charged platinum complexes are formed which in 
turns react with the nucleophilic sites  of  DNA. These complexes covalently 
binding  to the DNA bases by use of intra-strand and inter-strand cross-links 
creating cisplatin-DNA adducts. This adducts  will stop the  synthesis of  DNA, 
RNA and proteins. Cisplatin is cell cycle nonspecific agent. It  also act as 
immunosuppressant, and radiosensitizers. 
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Metabolism 
It is converted into several inactive metabolites non-enzymatically. These 
metabolites  are highly bound to plasma proteins. Rapidly diffuses and highly 
concentrated into body tissues .Primarily excreted through the urine. Terminal 
half life of ultrafilterable platinum 20-45 minutes and for total platinum  more  
than 5 days. 
Table -2Adverse effects 
Organ site  Side effects 
Auditory function ototoxicity (31%), 
abnormalaudiogram (24%), 
tinnitus (9%), vestibular toxicity rare. 
Haematology myelosuppression (25-30%) White 
Blood Cell nadir 18-23 days, platelet 
nadir 18-23 days , recovery 39 days 
,anemia (25-30%) 
Cardio vascular system 
 
vascular toxicities like myocardial 
infarction, cerebrovascular accident, 
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thrombotic microangiopathy or cerebral 
arteritis 
Allergy Hypersensitivity rarely occurs. 
GIT Highly emetogenic potential 
nausea and vomiting (> 90%) 
delayed nausea and vomiting. 
Renal Nephro toxicity 
Neurology  Peripheral neuropathies 
Liver Increased LFT 
Metabolic Electrolytes disturbances  
 
Dose 
40 mg/m2  weekly along with concurrent radiation. 
 Dose modification is needed in myelosuppression and renal failure. 
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Administration Guidelines 
Required dose of cisplatin injection is diluted  in 500 ml of normal saline 
and infused at a rate of 40 drops per minute over 2 hours. This diluted cisplatin 
should be used within 24 hours. Any unused dilution should be discarded. 
Continuous infusion over 24 hours will reduce the nausea, vomiting and renal 
toxicity.  
 
Recommended Clinical Monitoring: 
Complete Haemogram , initially and then regular monitoring.  Renal 
function tests including electrolytes , initially and then regular monitoring 
Liver function tests- baseline and regular. 
Clinical toxicity assessment for the following, neurotoxicity, ototoxicity 
and hypersensitivity, bleeding, infection, nausea and vomiting. 
 
PREVIOUS ARTICLE RELEVENT TO PRESENT STUDY 
A study on Palliative Hypofractionated Radiotherapy in Locally 
Advanced Head and Neck Cancer by Rajan Paliwal and team, Department of 
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Radiotherapy, Acharya tulsi Regional Cancer Treatment and Research Institute, 
Bikaner, Rajasthan University of Health Sciences, Jaipur, Rajasthan. India. 
The aim of the above study was to assess the symptomatic relief, tumor  
response and acute toxicity of palliative radiotherapy in locally advanced HNC 
patients. 
Methodology  
50 previously untreated, histopathologically proven locally advanced   
SCCHN patients with hard fixed cervical node were included in the study.  
Patients with stage IV disease with hard fixed cervical nodes, ECOG  
performance status II and III with life expectancy  of less than 1year were 
included. 
All the Patients were treated by external beam radiotherapy by using  
Cobalt-60 teletherapy machine .A total dose of 20Gy was given in 4Gy per 
fraction , total of  5 fractions in 5 consecutive days  of a week. 
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Patients characteristics: 
Table -3 
Patients details No.of.patients 
 
Response assessment 
Response  was assessed at 2 weeks  and 4 weeks post treatment. 
Sex Male 
Female 
40(80%) 
10 (20%) 
ECOG status 2 
3 
32 (64%) 
18 (36%) 
main symtoms Pain 
Dysphagia 
Hoarseness of voice 
Respiratory distress 
Other 
48 (96%) 
16 (32%) 
11 (22%) 
10 (20%) 
3  (6%) 
Primary site of the 
disease 
Tonsil  
Base of tongue 
Hypo pharynx 
Larynx 
Other 
 12 (24%) 
 11 (22%) 
 14 (28%) 
  6 (12%) 
  7 (14%) 
Tumor stage(T stage) T3 
T4 
27 (54%) 
23  (46%) 
Nodal stage (N) N2 
N3 
20 (40%) 
30 (60%) 
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Table -4  Symptom relief (a) 
 
 
Table – 5 Overall response (a) 
 
 
Table – 6 Acute toxicity 
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Conclusion 
In that study, they observed that two third of the patients presented with 
multiple symptoms and the short course of palliative radiotherapy provided  
appreciable symptom relief to more than 50% of the patients. At one month post 
palliative radiotherapy 92% of the patients showed partial response. Further 
radiotherapy was given according to the tumor regression status. 
 
It was concluded that unfavourable advanced and unresectable  HNC can 
be identified for a suitable short course palliative radiotherapy which will 
achieve growth restraint and durable symptom relief  in sizeable proportions of  
the  patients. 
 
 
 
 
 
 
  
 
 
AIM OF THE 
STUDY  
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AIM OF THE STUDY 
AIMS AND OBJECTIVES:  
 
PRIMARY OBJECTIVES 
To assess for degree of symptomatic relief & palliation. 
To assess the proportion of patients eligible for  radical  chemo radiotherapy. 
To assess immediate loco-regional disease control. 
 
SECONDARY OBJECTIVE 
To assess the acute toxicity to the treatment. 
 
 
 
 
 
 
 
 
 
  
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
This study is single arm prospective study involving  30 unresectable and 
advanced squamous cell carcinoma head and neck cancer patients. Thirty  
patients with histologically proved squamous cell carcinomas registered in our 
department were enrolled in this study. Enrolment  of the patients was started 
after obtaining consent from the ethical committee for conducting this study in 
our institute. The informed consent was obtained from all the patients  before 
including in the study. 
All  patients were given short course palliative radiotherapy of 20 
Gy.(400cGy per fraction for five fractions totally). Response was assessed after 
1 month of radiotherapy. Patients achieving  symptom relief of more than 50%, 
partial response at primary/nodal sites with good general condition were given  
further chemo radiotherapy at curative intent. For other patients best supportive 
care was given. 
 
INCLUSION CRITERIA: 
 Biopsy proven squamous cell carcinoma of the head & neck (SCCHN) 
 Primary tumour sites: oral cavity, oropharynx, hypopharynx, larynx 
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 Stage 4B disease 
 Stage 4A and Stage 3 disease with poor Performance status (PS) 
 ECOG performance status 2 and 3 
 Age < 70 years 
 Signed informed consent prior to initiation of protocol specific 
procedures 
 
EXCLUSION CRITERIA:  
 ECOG/PS 4 
 Inadequate hepatic, renal functions and bone  marrow reserve. 
 Previously received Radiotherapy or/and chemotherapy for any other 
malignancy 
 Tumours of nasal cavity, paranasal sinuses, nasopharynx and salivary 
glands 
 Non squamous histopathology and Metastatic disease. 
 Uncontrolled medical co-morbidities 
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INVESTIGATION DETAILS ( PRE TREATMENT WORK UP) 
Detailed history. 
Complete physical examination. 
Biopsy from the primary or metastatic node. 
Blood grouping. 
Clinical history/assessment. 
Complete haemogram. 
Renal function test(RFT) 
Liver function test( LFT) 
Fine needle aspiration cytology from doubtful lymph node 
Chest x-ray. 
ENT examination. 
Contrast enhanced computed tomography scan (CECT) of face and neck - At 
base line and after 1month of treatment. 
Base line symptom assessment by using symptom assessment scale (SAS). 
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PRE TREATMENT PATIENT PREPERATION 
Dental  care:  
Dental prophylaxis was done in all required patients. It includes  dental 
filling, scaling and extraction. In case of extraction of teeth, all patients were 
started on antibiotics, 2-3 days before to the extraction and then maintained on 
antibiotic coverage for 7 to 10 days. In already edentulous patient surgical 
removal of any symptomatic cysts and infected retained root tips were done. 
Complete oral hygiene instruction was given.  Following dental extraction rest 
time of 2 weeks was given for proper wound healing. 
Oral care: 
Most important therapy related toxicity in  head and neck cancer 
treatment is Mucositis . 
Patients were asked to gargle four  to six times a day  by using soda 
bicarb dissolved in water  especially after food during radiation. Patients 
developing oral candidiasis were treated with tablet Fluconazole 100 mg po for 
7 to 10 days. 
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Nutritional support: 
Most of  HNC patients lose weight due to cancer and treatment related 
toxicities. So nutrition management is very important to prevent/ reduce the 
treatment related complication like weight loss. Nutritionmanagement includes 
multidisciplinary team consists of dietitian, speech-language/swallowing 
therapist. 
Head and neck patients have  a specific feeding problems. All the patients 
were encouraged to take adequate nutrition to prevent excessive weight loss. 
Nasogastric tube is inserted if required. In extreme cases where nutritional 
intake by conventional methods is not possible as a  result of concurrent chemo 
radiation, parenteral nutrition is given. 
Specific meal plans were devised for individual patients. The meal plans 
were maintained as close to the normal diet as possible even when the texture 
and consistency were changed. The patient’s weight was checked  weekly  to 
evaluate the patients nutritional status. Depending on the weight the meal plans 
are revised once in a week. The meal plans are made  keeping in mind of the 
increased caloric and protein requirements of the patient for tissue regeneration. 
From the third week of treatment onwards the patients were advised to 
take liquid based diet as radiation induced reactions were started by that time. 
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Since the patients had radiation induced dysphagia and mucositis, the specific 
meal plan was changed to incorporate mainly liquid diet. During the fourth 
week of radiation  patients had developed xerostomia, so there was  difficulty in 
swallowing solid foods. Mucosal dryness will cause the solid foods to stick to 
mucosa and induces vomiting.  The patients were advised to take fresh juices 
like apple and guava and avoid citrus fruits like lemon and Mozambique. A 
special home- made high protein food using banana, egg, milk and sugar were 
advised twice daily.  
Nasogastric tube insertion or feeding jejunostomy and parenteral feeding 
was given to patients for whom oral feeding was not feasible.  
 
Smoking  cessation: 
Hypoxia due to high levels of carboxyhemoglobin in tobacco smokers 
coassociated with the poor treatment outcome. Hence strong motivational 
support is given to all patient to quit smoking before starting the study. 
 
PRE TREATMENT ASSESSMENT OF SYMPTOMS 
Before starting the treatment patients symptom was assessed by using 
symptom assessment scale (SAS). 
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Symptom assessment scale 
The Symptom Assessment Scale (SAS) describes the patient’s level of 
distress relating to individual physical symptoms. The instrument was designed 
to be a patient rated tool. 
How to assess? 
Patient can rate the degree of their distress for each symptom. If patient is 
not able to do so, family members/ attenders are asked to rate the degree of 
distress. But it is better for the patient to rate the symptoms on their own using 
the Symptom Assessment Scale for accuracy and consistency. 
Figure- 5;    11 point numeric scale 
11 point numeric scale was used to assess the symptom. 
 
If there is no Symptom, rating was given as  ‘0’.  If Symptoms present rating 
was given from 1 to 10.  
All the patients were told that, A score of 0: no symptoms 
A score of 1:minimal distress  
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A score of 10: the worst possible distress. 
Pain, dysphagia, dysnea, otalgia, cough and insomnia are the main distressing 
symptoms that were assessed. 
Assessment was done at baseline then every week after starting the treatment 
and at 1 month post treatment. 
 
PROTOCOL DESIGN 
A total of 30advanced and unresectable SCCHN patients  attending 
Radiotherapy  OP were recruited to the study. 
 
 
     
       Assessment  after 4 weeks 
 
 
 
Yes      No 
 
 
Palliative RT 20 Gy 
(400cGy/#, 5 #) for 1 week 
Partial response, symptom 
relief>50%, good PS 
 
Radical RT( to a total  
biologically equivalent dose 
of 66 Gy) +weekly cisplatin 
40mg/m
2 
Best supportive care 
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All patients were treated with 20Gy of radiotherapy in 5fractions of 
400cGy each. Response was assessed after 1 month of radiotherapy. Patients 
achieving  symptom relief of more than 50%, partial response at primary/nodal 
sites with good general condition were given further chemo radiotherapy at 
curative intent. 
Best  Supportive Care(BSC) was  given for other patients who were not 
showing  partial response and symptom relief of  less than 50% with poor 
general condition  at 1 month post treatment. 
RADIOTHERAPY TECHNIQUE 
Patients were treated by external beam radiotherapy delivered by Cobalt-
60 teletherapy machine (Theratron phoenix).  
POSITION  
Patients were treated in right and left lateral positions. 
PORTALS 
Patients  with disease crossing the midline and had bilateral presentation 
were treated by bilateral Parallel opposed fields  and dose was being prescribed 
to midline. 
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TREATMENT VOLUME 
Treatment volume included primary tumor site and  involved neck region  
plus 1 cm margin for setup error.  
DOSE OF PRT ( palliative radiotherapy) 
A total dose of 20Gy is given in 5 fractions in 5 consecutive days with a 
dose of 4Gy per fraction from day 1to day 5(from Monday to Friday). Surface 
bolus was used  for fungating lymph nodes.  
RESPONSE ASSESSMENT 
These patients were evaluated after 4 weeks of palliative radiotherapy and 
assessed for treatment response in terms of disease control(tumor regression) 
using RECIST criteria  and  degree of palliation of symptoms using Symptoma 
Assessment Scale(SAS). Acute toxicity grading was done as per RTOG 
(Radiation Therapy Oncology Group) toxicity criteria. Further treatment(chemo  
radiotherapy) was given  according to the tumor regression status. 
RESPONSE EVALUATION: at 4th week of palliative radiotherapy 
SUBJECTIVE RESPONSE 
Degree of symptomatic relief and palliation by using symptom 
assessment scale          
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Toxicity assessment—common toxicity criteria. (NCI CTCAE v 3.0) 
OBJECTIVE RESPONSE 
Objective response of primary and nodal tumor was  assessed  by 
clinically and radiologically  by using  response evaluation criteria in solid 
tumors (RECIST) 
COMPLETE RESPONSE(CR): 
Absence of residual disease after treatment 
PARTIAL RESPONSE (PR): 
30% decrease from baseline at 4
th
 week 
STABLE DISEASE (SD): 
Neither sufficient shrinkage nor sufficient increase  in  size. 
PROGRESSIVE DISEASE(PD): 
 20% increase from base line. 
 
FURTHER CHEMO RADIOTHERAPY 
Further Radiotherapy was delivered at 200cGy/#  to achieve a total  
biological equivalent dose (BED)  66 Gy with same radiation portals that were 
used in palliative radiotherapy(PRT). Further radiotherapy dose was  calculated 
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by the time-dose-fraction (TDF) method taking into account the dose fraction 
schedule of palliative radiotherapy (PRT) and the subquent gap in days.Spinal 
cord shielding was done at 40 Gy to avoid the dose to spinal cord.This further 
radiotherapy was  given along with weekly chemotherapy of inj. Cisplatin 40 
mg/m
2
. 
 
CHEMOTHERAPY 
All blood parameters like complete blood count (CBC)and the basic 
metabolic parameters were assessed before the start of every cycle of 
chemotherapy. Inj.cisplatin 40mg/m
2 
 was given concurrently with further 
curative intent radiotherapy. 
 
PREMEDICATION 
All patients were given the following premedication half an hour before 
starting  thechemotherapy. 
1. Inj. Dexamethasone 8 mg iv 
2. Inj. Rantac 150 mg iv 
3. Inj. Avil 1 4mgiv 
4. Inj. Ondanseteron 8 mg iv 
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After  premedication, patients were given prehydration with 500 ml of 
normal saline. Cisplatin was given in 500 ml normal saline infusion at a rate of 
40 drops per minute.Inj. Mannitol 175 ml IVgiven immediately after 
inj.cisplatin. After mannitol injection,  hydration was again done by using 500 
ml of normal saline. The entire chemotherapy procedure was completed within 
4 hours. The radiation therapy was given within one hour of completion of 
chemotherapy. The patients were given inj. Ondanseteron 8 mg IV bd  daily for 
three weeks. 
 
ASSESSMENT IN BETWEEN TREATMENT 
Toxicity of radiotherapy the following toxicities were assessed during 
every week of radiation. 
Skin reactions 
Mucositis 
Dysphagia 
Xerostomia  
Laryngitis 
Toxicity ofchemotherapy (Cisplatin)  
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the following toxicities were assessed during every week of treatment. 
Nausea 
Vomiting 
Renal function alteration 
Peripheral neuropathy 
 
TOXICITY MANAGEMENT 
The nausea and vomiting were managed by antiemetics, ondanseteron 8 
mg iv twice daily. The patients were also given adequate i v fluids to prevent 
dehydration. If any alteration in the renal parameters noted, nephrology opinion 
was sought and the dose of cisplatin was modified accordingly. 
The toxicities were assessed using RTOG Acute Morbidity Scoring 
Criteria and Common Toxicity Scoring Criteria. The toxicities were assessed 
every Monday and recorded. All the toxicities were managed according to the 
guidelines. 
For prevention of mucositis all patients were advised to maintain good 
oral hygiene and Soda bicarb mouth wash gargling 5 -6 times a day. Patients 
were also instructed to apply honey 15 minutes prior to the radiation, 15 
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minutes after radiation and 12 hours after radiation. During the radiotherapy, if  
patients developed mucositis, they were treated by using analgesics(NSAIDS),  
low dose steroids and antibiotics. NSAIDS used was Diclofenac sodium tablets 
50 mg twice daily. The steroid used was dexamethasone 4 mg IV twice daily if 
the patients developed grade III mucosities. All patients with grade III mucositis 
were treated with antibiotic, Cephalexin 500 mg four times daily. NSAIDS and 
antitussives was given forof grade II pharyngitis and laryngitis .Steroids  were 
included in the management of all grade III toxicities. 
Hemoglobin was checked every week. If hemoglobin level went below 
10 mg%, the patients were given packed cell transfusion. 
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TABLE - 7: RTOG Acute Morbidity Scoring Criteria 
 
Grade 
 
0 
 
1 
 
2 
 
3 
 
4 
 
MUCO
SITIS 
 
No 
Change 
 
Injection / 
Mild pain 
not requiring 
analgesic 
 
Patchy 
mucositis 
Moderate 
pain needs 
analgesia 
 
Confluent 
Mucositis 
Severe 
pain, needs 
morphine 
 
Ulceration, 
hemorrhage 
and Necrosis 
 
DERM
ATITIS 
 
No 
Change 
 
Follicular, 
faint, dull 
erythema/ 
epilation/ 
desquamatio
n 
 
Tender, 
bright patchy 
moist 
desquamation 
 
Confluent 
moist 
desquamati
on 
 
Ulceration, 
hemorrhage 
and Necrosis 
 
SALIV
ARY 
GLAND 
 
No 
Change 
 
Mild dryness 
/ Altered 
taste 
 
Moderate to 
complete 
dryness 
 
--------- 
 
Necrosis 
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PHARYNX 
 
No Change 
 
Mild 
dysphagia 
requiring 
analgesics 
 
Moderate 
dysphagia 
requires 
narcotics. 
Liquid 
diet 
 
Requires 
IV fluids 
or NG 
tube 
 
Ulceration, 
perforation 
and fistula 
 
LARYNX 
 
No Change 
 
Mild 
Hoarsenes
s, 
Cough 
doesn
,
t 
need 
treatment 
 
Persistent 
hoarsenes
s, 
Cough 
requiring 
antitussiv
e 
 
Whispere
d speech, 
throat 
pain 
requiring 
narcotics 
 
Dyspnea/ 
stridor, 
hemoptysi
s with 
tracheosto
my 
 
WBC 
(X1000) 
 
>= 4.0 
 
3 – 4 
 
2 – 3 
 
1 – 2 
 
<1 
 
PLATELE
T (X1000) 
 
>=100 
 
75 – 100 
 
50 – 75 
 
25 – 50 
 
< 25 or 
spontaneo
us 
bleeding 
 
HEMOGL
OBIN 
(gm %) 
 
>11 
 
9.5 – 11 
 
7.5 – 9.5 
 
5.0 – 7.5 
 
------- 
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FOLLOW UP OF PATIENTS RECEIVING FURTHER CHEMO 
RADIOTHERAPY 
Patients received  further chemo radiotherapy with curative intent were 
assessed for disease status 6 weeks after the treatment subjectively and 
objectively( by computed tomography). Patients were followed up every month 
thereafter. 
 
BEST SUPPORTIVE CARE FOR PATIENTS NOT GOING FOR 
FURTHER CHEMO RADIOTHERAPY 
Poor responders (symptom relief of less than 50% and patients not 
showed partial response)with poor general condition at assessment  after1 
month  of palliative radiotherapy of 20 Gy, were not taken up for further chemo 
radiotherapy. Best supportive care(BSC) was given to these patients. 
 
Supportive care was given in respect to the following aspects. 
Management of  cancer pain,  vomiting , cancer and treatment related 
anemia,  fatigue due to cancer and distress management. 
Prevention and treatment of infections due to cancer .  
Palliative care and nutrition support. 
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Pain management 
All patients were registered in palliative care OP department. After 
assessing the patients properly, T.morphine 5mg fourth hourly/ six times a day 
was given along with anti depressants, sedatives and laxatives. All the patients 
were reviewed once in a week. 
Packed cell transfusion was given to the required patients. Proper 
cleaning and dressing was done for ulcerated, fungated nodes and skin 
involving primaries. Patients were kept on higher antibiotics coverage for 7 to 
10 days. 
Nutrition support 
Adequate nutrion support was given to all patients. Naso Gastric tube 
insertion and feeding was done for patients not taking orally. All patients were 
advised to fresh juices like apple and guava. A special home- made high protein 
food using banana, egg, milk and sugar were advised twice daily. Protien 
powder contains high calorie   rich in protiens was given to all patients. for 
extreme cases, parenteral nutrion was given. All the patients were reviewed 
once in a week.  
 
 
  
CASE ANALYSIS 
AND RESULTS  
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RESULTS 
AGE DISTRIBUTION 
Totally  30 patients were enrolled in the study. Eligible age limit for the study 
was from 18 to 70 years of age. 
Table - 8 
AGE GROUP (in Years) NO.OF.PATIENTS PERCENTAGE(%) 
30 – 40      3 10 
40 – 50      5 16.6 
50 – 60     12 40 
60 – 70     10 33.3 
 
The age of the patients ranged from 34 to 68 years. The median age of the 
patients included  in the study was 56 years. Age distribution analysis of the 
sample showed that, most of the patients were in age the group of above 50 
years.  Age of the youngest patient included in the study was of 34 years;  age 
of the  eldest patient was of 68 years old. 
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SEX DISTRIBUTION 
The study group consists of  24 males and 6 females. 
This skewed selection towards the male gender was probably due to the 
increased exposure of carcinogens in male than females.  
Table-9; sex distribution 
SEX NO.OF.PATIENTS (%) 
MALE 24(80%) 
FEMALE 6 (20%) 
 
ECOG PERFORMANCE STATUS 
Table -10 
ECOG STATUS NO.OF.PATIENTS (%) 
ECOG 2 22(73.3%) 
ECOG 3 8(26.7%) 
 
Patients with poor performance status ( ECOG 2 and 3) and high disease 
burden Were included in the study. 
 
 AGE DISTRIBUTION 
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SITE DISTRIBUTION 
 
 
22 
8 
0
5
10
15
20
25
ECOG 2 ECOG 3
No.of.patients
13 
11 
4 
2 
No.of patients 
oral cavity
oropharynx
hypo pharynx
larynx
87 
 
SITE DISTRIBUTION: 
The site wise distribution of the cancers  patients included in the study 
showed, majority of the patients were of oral cavity and oropharyngeal 
carinoma. 
Table -11 
Site No.of.patients Percentage(%) 
Oral cavity   13 43.3 
Oropharynx   11 36.7 
Hypopharynx    4 13.3 
Larynx    2 6.7 
 
SUBSITE INVOLVEMENT: 
ORAL CAVITY -SUB SITE DISTRIBUTION 
The patients with oral cavity cancers had involvement of the anterior 
2/3rd of the tongue in 5 patients; buccal mucosa in 3 patients; alveolar ridge in 3 
patients; floor of mouth in 1 patient and  hard palate in 1 patient. 
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Table-12 
Sub site No.of.patients 
Anterior 2/3 rd tongue  5 
Buccal mucosa  3 
Alveolar ridge  3 
Floor of mouth  1 
Hard palate  1 
 
HYPO PHARYNX-SUB SITE DISTRIBUTION 
Table- 13 
Sub site No.of.patients 
Pyriform fossa  3 
Post cricoids  1 
 
In hypo pharyngeal cancers patients, 3 of them pyriform fossa  involvement and 
1 post cricoid region involvement.  
LARYNX- SUB SITE DISTRIBUTION 
Two supraglottic cancer patients were included in the study. 
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OROPHARYNX- SUBSITE DISTRIBUTION 
Table-14 
Sub site No.of.patients 
Posterior 1/3
rd
 tongue  5 
Tonsillar fossa  4 
Soft palate  2 
 
In cancer of the oropharynx patients, involvement of the posterior one 
third tongue in 5 patients; tonsillar fossa in 4 patients and the soft palate in 2 
patients. 
 
PRIMARY TUMOR CHARECTERISTICS 
Table -15;  T STAGE 
T stage No.of.patients 
T2  5 
T3  9 
T4a 11 
T4b  5 
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Majority of the patients were in T4 stage.  
5 patients in T2 stage; 
 9 patients were in T3 stage; 
 11patients were in T4a stage and 5 patients were in T4b stage. 
Table -16; N stage distribution 
N stage  No.of.patients 
N0  2 
N1  4 
N2a 7 
N2b 6 
N2c 6 
N3 5 
 
Majority of the patients were N2 stage 19. 
5  of the patients were in N3 stage. Out of them 4 patients were presented 
with ulcerated, fungating nodes.  
N0 nodal staging was found in 2  patients. 
N1 presentation was in 4 patients. 
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STAGE GROUPING 
Table –17 
Stage group No.of.patients 
Stage III  8 
Stage IVA  15 
Stage IV B   7 
 
Most of the patients were in stage  group IV A. 
DIFFERENTIATION 
Table -18 
Differentiation No.of.patients 
Well differentiated  3 
Moderately differentiated  5 
Poorly differentiated  22 
 
Poorly differentiated carcinomas accounts for 73.33%.  
Moderately differentiated cancers in 16.6%. Well differentiation was seen in 
10%. 
  
STAGE GROUPING 
 
 
SYMPTOM AT PRESENTATION 
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SYMPTOMS BEFORE PRT (Palliative Radiotherapy) 
Table -19; Symptoms at presentation 
Symptoms No.of.cases had that symptom 
Pain 25 (83%) 
Dysphagia 15 (50%) 
Cough 10 (33%) 
Otalgia 6 (20%) 
Dyspnoea 4 (13%) 
Voice change 5 (16%) 
Insomnia 23 (76%) 
 
Pain was the major compliant in 83% of the patients. 
Dysphagia, cough, otalgia, insomnia, dysnea and voice change was seen in 
50%, 33%, 20%,76%,13% and 16% of the patients respectively. 
Some  of the patients had all the above said symptoms, while others had half or  
more than half of  the above mentioned symptoms. 
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RESPONSE ASSESSMENT FOLLOWING PALLIATIVE 
RADIOTHERAPY 
Table -20 Over all response (b) (n=30) 
Type of response No.of.patients 
Partial response 23 (76.6%) 
Static response 4 (13.4%) 
Progressive disease 3(10%) 
Complete response 0(0%) 
 
SYMPTOM RELIEF 
Table -21  Symptom relief (b) 
Symptoms  No.of patients showed more 
than 50% symptom relief 
Pain (n=25) 20 (80%) 
Dysphagia (n=15) 11 (73%) 
Cough (n=10)  7 (70%) 
Otalgia (n=6)  4 (66%) 
Dyspnoea (n=4)  3(75%) 
 RESPONSE AFTER PALLIATIVE RADIOTHERAPY 
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Voice change (n=5)  2 (40%) 
Insomnia (n=23) 18 (78%) 
 
PROPORTION OF PATIENTS ELIGIBLE FOR FURTHER CHEMO 
RADIOTHERAPY WITH CURATIVE INTENT 
Out of  30 patients who received palliative radiotherapy, 16 patients were 
eligible  for further chemo radiotherapy with curative intent. Remaining 14 
patients were not fit for further treatment, so Best Supportive Care was given to 
them. 
Table – 22  Further chemo radiotherapy (n=30) 
Radiotherapy received No.of.patients 
Palliative radiotherapy  30 
Palliative RT  followed by Further chemo 
radiotherapy with curative intent. 
16 (53%) 
Palliative radiotherapy followed 
bysupportive care. 
14 (47%) 
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RESPONSE ASSESSMENT FOLLOWING CHEMO RADIOTHERAPY 
 1 month after the completion of the concurrent chemo radiation(with 
curative intent), the response rates were assessed.  
Table – 23 Over all response (c) (n=16) 
Response  No.of.patients 
Complete response  3 (18.75%) 
Partial response (presented with 
minimal residual disease) 
12  (75%) 
Static response  1 (6.25%) 
Progressive disease  0 (0%) 
 
Clinically complete response was seen in 3 (18.75%) cases. Static 
response was noted in 1 (6.25%) patients. No one has developed progressive 
disease. 
Locoregional control was very good in remaining 12(75%) patients. They 
were presented with very minimal residual disease at 1 month post treatment. 
 
 
 RESPONSE AFTER CHEMO RADIOTHERAPY (n=16) 
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ANALYSIS OF  THERESPONSE 
Clinically, complete response was achieved in 3 patients. All the 3 
patients were poorly differentiated carcinoma of posterior one third of tongue. 
All  the patients were belong to stage group IV A. Staging was T4A N2b 
M0 in one patient and T4a N1 M0 in two patients. 
Both the patients were in ECOG status 2.  
 
TOXICITY ASSESSMENT 
TOXICITY OF PALLIATIVE RADIOTHERAPY: 
 Total dose of 20 Gy was delivered in 4 Gy per fractions, total of 5 
fractions over 5 days a week. The toxicities of palliative radiotherapy were 
graded using RTOG acute morbidity scoring criteria. 
Mucositis:  
Majority of the patients developed grade 1 mucositis only. (20 patients). 
Grade 2 mucositis was noted in 10 patients. 
No patients were developed grade 3 or more toxicities due to treatment. 
The mucositis was managed with,  
97 
 
1. Inj. Dexamethasone 8 mg IV BD 
2. Soda Bicarbonate Mouth Wash every 3-4 hours. 
3. Alcohol free Antibacterial Mouthwash / oral lozenges. 
4. Dispersible pain killer tablets to relieve pain.  
 
Dermatitis: 
 This was not a significant problem in this study. Most of them had grade 
1 reaction only.  
No other toxicity was developed due to palliative radiotherapy. 
 
TOXICITY OF FURTHER CHEMO  RADIOTHERAPY: 
 Further chemo radiotherapy was delivered to patients who showed partial 
response, symptom relief of more than 50% with good general condition. It was 
given in 2 Gy per fractions upto a total dose of 66Gy radio biological equivalent 
with weekly Inj.Cisplatin 40 mg/m
2 
. 
The toxicities occurred during radiotherapy were graded using RTOG 
acute morbidity scoring criteria. 
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Mucositis:  
Majority of the patients developed grade 2 mucositis (11 patients).                   
2 patients developed grade 3 mucositis and treatment had to be suspended  to 
allow for the resolution of mucositis before proceeding with further radiation. 
 
Dysphagia: 
After palliative radiotherapy dysphagia was appreciably relieved in 
majority of the patients. Out of 16 patients who received further radiotherapy, 8 
patients showed  increased dysphagia (from grade 1 to grade 2). They were 
managed with pain killer and maintained on nutritious liquid diet. No patients 
developed grade 3 or more reactions. 
 
Dermatitis: 
Most of them developed grade 1 and grade 2 reactions which  was 
allowed to resolve by itself after the completion of treatment. 
  
TOXICITY OF PALLIATIVE RADIOTHERAPY 
 
Mucositis (n=30) 
Mucositis No. of. patients 
Grade 1 20 
Grade 2 10 
Grade 3 0 
Grade 4 0 
 
 
TOXICITY OF FURTHER CHEMO RADIOTHERAPY 
Mucositis (n=16) 
Mucositis No.of. patients 
Grade 1  3 
Grade 2 11 
Grade 3 2 
Grade 4 0 
 
            Dysphagia (n=16) 
Grade  No.of.patients 
Grade 1 7 
Grade 2 9 
Grade 3 0 
Grade 4 0 
           Dermatitis 
Grade  No. of. patients 
Grade 1 10 
Grade 2 6 
Grade 3 0 
Grade 4 0 
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Salivary gland toxicity: 
 Almost all of the patients who received further radiotherapy, have 
developed grade 2 toxicity at the  first assessment . But none had acute necrosis 
of the salivary gland. All of those who had xerostomia were prescribed artificial 
salivary supplements. 
Haematological toxicity 
The only haematological toxicity encountered during the study was 
anaemia.  None of the patients had neutropenia or thrombocytopenia. 
Table-24  Anaemia 
Grade  No.of. cases 
Grade 1 10 
Grade 2 4 
Grade 3 0 
 
TOXICITY OF WEEKLY CDDP: 
All the 16 patients received weekly Cisplatin  of 40 mg/m
2
during 
radiotherapy. They  received 4 cycles of chemotherapy. Nausea and vomiting 
was observed in most of the patients. 
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NAUSEA 
Table -25 
Grade  No.of  cases 
Grade 1  7 
Grade 2   9 
Grade 3  0 
 
Table – 26  VOMITTING 
Grade  No.of  cases 
Grade 1  9 
Grade 2  2 
Grade 3  0 
Grade 4  0 
 
Nausea and vomiting was managed with, 
IV fluids to correct dehydration, if any. 
Metoclopramide 40 mg PO every 4–6 hours for 4 days. 
Dexamethasone 4-8 mg IV BD for 4 days. 
  
 
 
DISCUSSION  
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DISCUSSION 
M ajority of these cases (60%-80%)in India are presented in advanced 
stage. Management of these cases with curative approach has evolved 
considerably over the time. There was lot of randomized control trials, meta 
analyses and  volume of literatures on this already. Radical treatment in the 
form of aggressive multi modality approach is not successful in  all of these 
patients because of poor performance status and unresectability. These 
advanced and unresectable cases need palliative treatment and/or best 
supportive care. 
 
There  is no general consensus Regarding palliative schedule in SCCHN. 
Many palliative regimens are recommended. Weissberg et al
51
 evaluated 
conventional fractionated radiotherapy versus hypofractionated palliative radio 
therapy  schedules for patients with locally recurrent or advanced HNC. They 
compared 60 Gy to 70Gy over 6 to 7 weeks with 40 Gy to 48 Gy in 64patients 
with stages III and IV surgically unresectable SCCHN. No difference was 
observed in terms of tumor control, acute toxicity and chronic toxicity. 
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Sushmita Ghoshal et
52 
al (2004) conducted another study to assess the 
role of palliative radiotherapy for symptom control in patients with locally 
advanced SCCHN. In that study, 25 cases with stage 3 and 4 HNC were treated 
with a short course of palliative radiotherapy of 30 Gy, 3 Gy per fraction, in 10 
# over two weeks. Baseline symptoms were assessed using an 11 point 
numerical scale for pain, dysphagia, cough, insomnia and dyspnea. The primary 
end point of the study was relief of symptoms at 4th week after radiotherapy. 
All 22 patients with pain and 90% of patients with dysphagia, dyspnea and 
disturbed sleep had greater than 50% relief in symptoms after radiotherapy. 
Cough was relieved in 60% of cases. 
In another study conducted by Rajan paliwal et
42
 al, palliative 
radiotherapy dose of 20Gy was delivered  in 5# in 5 consecutive days with a 
dose of 4Gyper fraction.52% patients presented with main complaint of pain 
and 32% of patients with dysphagia, after radiotherapy more than 76% got relief 
from pain and more than 66% patients got relief from dysphagia. Further 
radiotherapy was given according to the tumor regression status of palliative 
radiotherapy. 
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However concurrent chemo radiation can be tried in these patients as a dose 
escalation after palliative radiotherapy. In this study, after initial palliative 
radiotherapy with high dose per fractionation, appreciable palliation and partial 
response was achieved in majority of the patients. Tumor burden and distressing 
symptoms was minimized some extent after palliative radiotherapy. So, these 
patients were given chemo radiation for curative intent.  
PREVIOUS DOSE ESCALATION STUDIES 
Ali My et
44
 al conducted a study comprising 30 locally advanced SCCHN 
patients who were treated initially by palliative radiotherapy 30 Gy  in 3 Gy per 
fractions. Patients achieving >50% symptom relief and partial response at 
primary and nodal site and in good general condition  after one month of 
palliative radiotherapy  were taken up for further radiotherapy with curative 
intent. Further radiotherapy was given in 2 Gy per fractions upto a total  
radiobiologically equivalent dose of 66 Gray  with same radiation portals that 
were used in PRT.  
Spinal cord shielding was done at 40 Gy. It  was calculated by Time-
Dose-Fractionation (TDF) method taking into account the dose fraction of 
palliative radiotherapy with gap correction. 
Following studies are supporting the dose escalation of this study. 
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Table -27PREVIOUS STUDIES 
Study name Radiotherapy 
dose used 
No.of.patients 
showed partaial 
response 
No.of patients 
given further 
radiotherapy 
Mohanti et al
39
 
(n= 505) 
20 Gy, 4Gy/#,5# 189(37%) 153(30%) 
Ali My et al
44 
(n=30) 
30Gy,3Gy/#,10# 14 (47%),  
CR-8(27%) 
 8 (27%) 
Rajan Paliwal 
et al
42
 (n=50) 
20 Gy,4Gy/#,5# 46 (92%),  
CR-4(8%) 
Further RT 
given (number 
not 
mentioned) 
 
Mohanti et al 
39
 conducted a study on 505 patients with stage IV SCCHN. 
All patients were given 20 Gray of palliative radiotherapy, 4Gray/#, 5 # over 
one week. 70% percent of cases complained of two or more distressing 
symptoms at presentation. On assessment at one month after the palliative 
radiotherapy, 189 patients  (37%) attained a partial response and had 
ambulatory physical state well suited for further radiotherapy with intent. Good 
symptom relief (50% or more) was seen in 57% for pain, 53% for difficulty in 
swallowing, 57% for voice change, 47% for ear pain, 76% for dyspnoea and 
59% for cough. The main acute toxicity of Palliative radiotherapy was            
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grade II mucositis and dermatitis. Median overall survival was 200 and 400 
days in patients receiving palliative radiotherapy and further radiotherapy 
respectively. 
In the present study complete response rate after chemo radiation was 
seen in 3 out 30 study patients (10%).  
Mohanti et al
39.
alsorecorded the same that around  10 % of the patients 
were disease free after further radiotherapy. 
 
Toxicity  
Previous studies has concluded that due to palliative nature of the 
treatment, late tissue toxicities were not a significant problem in the patients 
received  short course palliative radiotherapy. Significant chronic xerostomia 
and other late toxicities of evaluable patients were acceptable and were not dose 
dependant. So patients received further radiotherapy did not have any worst late 
toxicity as compared to patients received initial palliative radiotherapy alone. 
 
In the present study, more than 50 % symptom relief was noted in 80% of 
the patients with pain, 73% of the patients with dysphagia, 70% of the patients 
with cough, 66% of the patients with otalgia, 75% of the patients with 
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dyspnoea, 40% of the patients with voice change and 78% of the patients with 
insomnia. The main acute toxicity of palliative radiotherapy was more or less 
same to the above mentioned studies. Assessment at 1 month after  palliative 
radiotherapy showed partial response rate of 76.6% (n=23). 
 
In the present study,  majority of the cases presented with multiple 
symptoms and the short course of palliative radiotherapy offered appreciable  
symptom relief quickly in these patients. 
 
Further chemo radiotherapy was given in 53% (n=16)of the patients. 
These patients were tolerated further chemo radiotherapy reasonably. None of 
them developed grade III or more toxicities. No one was died due to treatment 
toxicity. Among 16 patients who received further chemo radiotherapy, 3 
patients showed complete response at 1 month post chemo radiotherapy. 
Supportive care was given to the remaining patients.  
 
In summary the present study shows that hypofractionated short course 
palliative radiotherapy is better and effective for  unresectable ,advanced and 
poor PS (Performance Status) patients. This study also helps in finding the 
patients for further chemo radiotherapy. 
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Limitations of the study 
It is a known fact that even a single day of delay in the radiotherapy 
schedule is detrimental to the final outcome due to tumor re-population.  In this 
study there was a  treatment gap of 1 month between palliative radiotherapy and 
further chemo radiotherapy with curative intent. Because of that treatment delay 
and also due to extensive disease burden, majority of the patients left with 
residual disease after further chemo radiotherapy. Only 10 % of the study 
patients(n=30) were disease free after further chemo radiotherapy. However, it 
(tumor repopulation) is not a major issue in a palliative setting. 
 
There was no long term follow up of the patient which would have given 
the duration of symptom relief and overall survival of the patients. 
 
 
 
 
 
 
  
 
CONCLUSION  
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CONCLUSION 
In conclusion, head and neck cancers are the major public health problem 
in a developing country like India. Most of these patients  presented with the 
advanced and  unresectable stages. Most  of them are not suitable for aggressive 
multi modality radical chemo radiotherapy or  long duration palliative 
radiotherapy because of poor general condition of the patients and incurable 
nature of the disease. So short course  hypofractionated radiation is effective for 
palliation to relieve the symptoms quickly with manageable side effects in these 
advanced and unresectable HNC cases.  
As we see in the present study, short course palliative radiotherapy can 
effectively restrain the growth, relieve symptoms and thereby increases the 
quality of life of the patients. 
This study also helps in selecting the patients for further chemo 
radiotherapy based on tumor regression and symptom relief after palliative 
radiotherapy. 
Also, this study is trying to strike a balance between economic burden, 
treatment time and hospital stay and machine load. 
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ANNEXURE I 
HEMATOLOGICAL TOXICITY 
 
Grade  0 1 2 3 4 
HEMATOLOGIC 
WBC (X 1000) 
>=4.0 3.0 - <4.0 2.0 - <3.0 1.0 - <2.0 <1.0 
PLATELETS (X 
1000) 
>=100 75 - <100 50 - <75 25 - <50 <25 or 
spontaneous 
bleeding 
NEUTROPHILS >=1.9 1.5 - <1.9 1.0 - <1.5 0.5 - <1.0 <0.5 or sepsis 
HEMOGLOBIN 
(GM %) 
>11 11-9.5 <9.5 - 7.5 <7.5 - 5.0 - 
 
 
 
 
 
 
 
 
 
 
ANNEXURE II 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
CTCAE VERSION 4. 
 
GRADE 1 2 3 4 5 
NAUSEA Loss of 
appetite 
without 
alteration 
in eating 
habits 
Oral intake 
decreased 
without 
significant 
weight loss, 
dehydration 
or 
malnutrition. 
Inadequate 
oral caloric or 
fluid intake, 
tube feeding, 
TPN, or 
hospitalization 
indicated. 
- - 
 
 
Grade  1 2 3 4 5 
vomitin
g 
1-2 
episodes  
(separate
d by 5 
minutes) 
in 24 hrs 
3-5 
episodes 
(separate
d by 5 
minutes) 
in 24 hrs 
>/=6 episodes 
(separated by 5 
minutes) in 24 
hrs,tubefeeding,TP
N or 
hospitalization 
indicated 
Life-threatening 
consequences,urge
nt intervention 
indicated 
deat
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ANNEXURE III 
INFORMATION SHEET 
• You have been accepted by the Department of Radiotherapy to enroll into 
the study “SHORT COURSE PALLIATIVE RADIOTHERAPY FOLLOWED 
BY CHEMORADIATION WITH CURATIVE INTENT IN ADVANCED 
AND UNRESECTABLE HEAD AND NECK CANCER” 
 
• We are conducting a study on head and neck cancers among patients 
attending Government General Hospital, Chennai.  
 
• The purpose of this study is to find if prior treatment of chemotherapy 
followed by concurrent chemoradiation will have a better response rates and 
lower recurrences.  
 
• We are selecting certain cases and if your case is found eligible, we may 
be performing extra tests and special studies which in any way do not decrease 
your chance of optimum treatment.   
 
• The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared.  
 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled.  
 
• The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment.  
 
Signature of investigator         Signature of participant 
ANNEXURE IV 
 
INFORMED CONSENT FORM 
TITLE OF THE STUDY: “SHORT COURSE PALLIATIVE 
RADIOTHERAPY FOLLOWED BY CHEMORADIATION WITH 
CURATIVE INTENT IN ADVANCED AND UNRESECTABLE HEAD AND 
NECK CANCER” 
NAME OF THE PARTICIPANT: 
NAME OF THE PRINCIPLE (Co – Investigator) : DR.S.VIJAYAKUMAR 
NAME OF THE INSTITUTION: MADRAS MEDICAL COLLEGE 
 
I,_____________________________ have read the information in this form (or 
it has been read to me). I was free to ask any questions and they have been 
answered. I am over 18 years of age and, exercising my free power of choice, 
hereby give my consent to be included as a participant in “SHORT COURSE 
PALLIATIVE RADIOTHERAPY IN ADVANCED AND UNRESECTABLE 
HEAD AND NECK CANCER” 
1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have informed the investigator of all the treatments I am taking or have 
taken in the past________ months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study.* 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer 
unusual symptoms. * 
8. I have not participated in any research study within the past 
_________month(s). * 
9. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital. * 
10. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. * 
11. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
12. I understand that my identity will be kept confidential if my data are 
publicly presented 
13. I have had my questions answered to my satisfaction. 
14. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in 
this document has been clearly explained to me and understood by me, I will be 
given a copy of this consent document. 
Name and signature / thumb impression of the participant 
Name ________________ Signature_________________ 
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name ________________ Signature_________________ 
Date_______________ 
 
 
 
 
 
ANNEXURE V 
ஆபாய்ச்சி தகவல் தாள்: 
 
ஆபாய்ச்சியின் ப஧னர் 
 
தல஬ நற்றும் கழுத்து ஧குதியில் மிகவும் முற்றின புற்றுந஥ாய்க்கு ஒரு 
வாபத்திற்கு தீவிப கதிர்வீச்சு சிகிச்லை ௮ளித்த பி஫கு ஥ா஦ஂ குவாபங்கள் 
கழித்து ,கதிபஂ வீைஂ  சி஦ஂ  ஧஬ல஦ ஆபானஂ ஥ஂ   து  ஧஬னுகஂ நக஫ஂ  ஧ நதலவ஧ஂ ஧டி஦ஂ   
மீணஂ டுநஂ  ஒரு நாத கா஬த்திற்கு கதிர்வீச்சு சிகிச்லையுட஦ஂ  பு஫ஂ றுந஥ானஂ   
நரு஥ஂ துநஂ   ௮ளித்து புற்றுந஥ாலன குணப்஧டுதஂ த முன஫ஂ  ைஂ  சி஧ஂ஧து ஧஫ஂ றின 
ஆய்வு. 
 
           பைன்ல஦ இபாஜீவ்காந்தி ௮பசு ப஧ாது ந௫த்துவநல஦க்கு வரும் 
புற்று ந஥ானாளிகளிடம் கதிர்வீச்சு சிகிச்லைப் ஧ற்றின ஆபாய்ச்சி. 
 
            தல஬ நற்றும் கழுத்து ஧குதியில் முற்றின புற்றுந஥ாய்க்கு ஧஬ 
வலகனா஦ கதிர்வீச்சு சிகிச்லை முல஫கள் ௨ள்஭஦.௮வற்றுள் 
குணப்஧டுத்த முடினாத மிகவும் முற்றின புற்றுந஥ாய்க்கு முதலில்  ஒரு 
வாபத்திற்கு தீவிப கதிர்வீச்சு சிகிச்லை ௮ளித்த பி஫கு ஥ா஦ஂ குவாபங்கள் 
கழித்து ,கதிபஂ வீ ைஂ   சி஦ஂ   ஧஬ல஦ ஆபானஂ ஥ஂ  து  ஧஬னுகஂ நக஫ஂ ஧ நதலவ஧ஂ ஧டி஦ஂ   
மீணஂ டுநஂ  ஒரு நாத கா஬த்திற்கு கதிர்வீச்சு சிகிச்லையுட஦ஂ  பு஫ஂ றுந஥ானஂ   
நரு஥ஂ துநஂ௮ளித்து புற்றுந஥ாலன குணப்஧டுதஂ  த முன஫ஂ  ைஂ சி஧ஂ஧து இந்த 
ஆபாய்ச்சியின் ந஥ாக்கம். 
 
           நீங்களும் இந்த ஆபாய்ச்சியில் ஧ங்நகற்க  விரும்புகிந஫ாம்.இந்த 
ஆபாய்ச்சியில் தீவிப  கதிர்வீச்சு சிகிச்லை ௮ளித்து சி஬ சி஫ப்பு  
஧ரிநைாதல஦க்கு ௨ட்஧டுத்தி ௮தன் தகவல்கல஭ ஆபாய்நவாம்.இத஦ால் 
தங்கள்  ந஥ாயின் ஆய்வறிக்லகநனா சிகிச்லைநனா ஧ாதிப்பு  எற்஧டாது 
என்஧லத  பதரிவித்துக் பகாள்கிந஫ாம். 
 
           முடிவுகல஭ ௮ல்஬து கருத்துகல஭ பவளியிடும் ந஧ாநதா ௮ல்஬து 
ஆபாய்ச்சியின் ந஧ாநதா தங்களின் ப஧னலபநனா ௮ல்஬து 
௮லடனா஭ங்கல஭நனா பவளியிட நாட்நடாம் ௭ன்஧லதயும் 
பதரிவித்துக் பகாள்கிந஫ாம். 
 
           இந்த சி஫ப்பு ஧ரிநைாதல஦களின் முடிவுகல஭யும் ந஥ாயின் தன்லந 
஧ற்றியும் ஆபாய்ச்சியின் முடிவின் ந஧ாது தங்களுக்கு ௮றிவிப்ந஧ாம் 
௭ன்஧லதயும் பதரிவித்துக் பகாள்கிந஫ாம். 
 
ஆபாய்ச்சினா஭ர் லகபனாப்஧ம்   ஧ங்நகற்஧ா஭ர்  லகபனாப்஧ம் 
நததி:        நததி:  
           
ANNEXURE VI 
ஆபாய்ச்சி ஒப்புதல்  கடிதம் 
ஆபாய்ச்சினா஭ர் ப஧னர்:   நததி: 
 
வனது:      ௨ள்/பு஫ ந஥ானாளி எண்: 
 
஧ால்:       ஆபாய்ச்சி நைர்க்லக எண்: 
 
஧ங்நகற்஧ா஭ர் ப஧னர்: 
 
 
தல஬ நற்றும் கழுத்து ஧குதியில் மிகவும் முற்றின புற்றுந஥ாய்க்கு 
ஒரு வாபத்திற்கு தீவிப கதிர்வீச்சு சிகிச்லை ௮ளித்த பி஫கு஥ா஦ஂ  குவாபங்கள் 
கழித்து ,கதிபஂ வீைஂ  சி஦ஂ  ஧஬ல஦ ஆபானஂ ஥ஂ  து  ஧஬னுகஂ நக஫ஂ ஧ நதலவ஧ஂ ஧டி஦ஂ   
மீணஂ டுநஂ  ஒரு நாத கா஬த்திற்கு கதிர்வீச்சு சிகிச்லையுட஦ஂ  பு஫ஂ றுந஥ானஂ   
நரு஥ஂ துநஂ   ௮ளித்துபுற்றுந஥ாலன குணப்஧டுதஂ த முன஫ஂ  ைஂ சி஧ஂ஧து ஧஫ஂ றின 
ஆய்வு. 
 
 இந்த ஆபாய்ச்சியின் விவபங்களும் ௮தன் ந஥ாக்கங்களும் 
முழுலநனாக ௭஦க்கு வி஭க்கப்஧ட்ட஦. 
 ௭஦க்கு வி஭க்கப்஧ட்ட விவபங்கல஭ ஥ான் புரிந்துபகாண்டு ௭஦து 
ைம்நதத்லத பதரிவிக்கிந஫ன். 
 ௭஦க்கு புற்றுந஥ாய் இருக்கும் ஧குதியில் கதிர்வீச்சு சிகிச்லை 
பைய்து பகாள்஭ ைம்நதம். 
 இந்த ஆபாய்ச்சியில் பி஫ரின் நிர்ப்஧ந்தமின்றி ௭ன் பைாந்த 
விருப்஧த்தின் ந஧ரில் ஧ங்கு ப஧றுகிந஫ன்.இந்த ஆபாய்ச்சியில் இருந்து 
஥ான் ௭ந்ந஥பமும் பின்வாங்க஬ாம் ௭ன்஧லதயும் ௮த஦ால் ௭ந்த 
஧ாதிப்பும் ஏற்஧டாது ௭ன்஧லதயும் ஥ான் புரிந்து பகாண்நடன். 
 ஥ான் தல஬ நற்றும் கழுத்து ஧குதியில் முற்றின புற்று ந஥ாய் குறித்த 
இந்த ஆய்வுக்கா஦ விவபங்கள் பகாண்ட தகவல் தால஭ப் ப஧ற்றுக் 
பகாண்நடன். 
 ௭஦க்கு இந்த ஆபாய்ச்சியில் தீவிப கதிர்வீச்சு சிகிச்லை ந஫ஂ றுநஂபுற்று 
ந஥ாய்நரு஥ஂ துப஧ற்றுக் பகாள்஭ ைம்நதம். 
 இந்த ஆபாய்ச்சியி஦ால் ஏற்஧டும் ஥ன்லநகல஭யும் , சி஬ 
஧க்கவில஭வுகல஭யும் ஧ற்றி பதளிவாக நருத்துவர்  மூ஬ம் 
பதரிந்துபகாண்நடன். 
 ஥ான் ௭ன்னுலடன சுனநில஦வுடனும் நற்றும் முழு 
சுதந்திபத்துடனும் இந்த நருத்துவ ஆபாய்ச்சியில் ௭ன்ல஦ நைர்த்துக் 
பகாள்஭ ைம்நதம் பதரிவிக்கிந஫ன்.   
        
ஆபாய்ச்சினா஭ர் லகபனாப்஧ம்   ஧ங்நகற்஧ா஭ர்  லகபனாப்஧ம் 
நததி:      நததி: 
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